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I. INTRODUCTION 
Theoretical Framework: "The fundamental focus of case management is to 
integrate, coordinate, and advocate for individuals, families, and groups requiring 
extensive services, ensuring that patients receive appropriate, individualized and 
cost-effective care within a system of services.”1 It is a system of patient care that 
focuses on the achievement of outcomes within specified time frames and with the 
appropriate use of resources. The emphasis of care changes from a task orientation 
to the outcomes of medical and nursing interventions throughout an episode of 
illness and/or treatment. 
Case management is an effective method for use in tuberculosis control to ensure 
patients complete treatment. This model utilizes a team concept and is based on a 
philosophical and practical approach built on trusting relationships with the patient 
as a partner, which provides individualized care, patient education, advocacy, and 
promotes adherence and treatment completion. 
Goal: To have patients complete an appropriate and effective course of anti-
tuberculosis treatment in the shortest time possible, without interruption in therapy, 
using the least restrictive measures indicated. 
Treatment Standard of Care: Evaluate every suspected and confirmed case of 
tuberculosis for the need for directly observed therapy (DOT) based on an 
assessment of risk factors for non-adherence. For persons on therapy for TB 
disease without any known risk factors for nonadherence, the Division 
recommends self-administered therapy, using fixed-dose combination pills (rifater 
for the initial phase and rifamate for the continuation phase) as the standard of 
care. 
Legal Authority: The Commonwealth of Massachusetts Regulations, Standards for 
Management of Tuberculosis Outside Hospitals, 105 CMR 365.000 provides the 
legal authority for tuberculosis control in Massachusetts. These protocols and 
standards were developed based on this regulatory framework. 
A. Nursing Case Management Model: 
1. Indirect Case Management 
In Massachusetts (outside Boston), every suspect and confirmed case of TB is 
currently referred to the Tuberculosis Surveillance Area (TSA) nurse. The regionally-
1Bower, K. Nursing Case Management, Kansas City, MO, 1992, American Nurses Association 
Publishing Co. 
October 2001 5 
based TSA nurses are notified of potential cases through several mechanisms: 1) 
formal reports from the health care providers or local health departments to the 
Division, 2) receipt of a positive bacteriology smear or culture report from the State 
Mycobacteriology Laboratory, 3) receipt of a TB clinic form for a patient seen at 
one of the 27 state-funded TB clinics, or 4) a telephone call from a local health 
department/Board of Health (BOH) nurse or other health care provider. 
The TSA nurses provide consultative support to the local BOH nurses who have the 
responsibility for direct patient management. This follow-up on the local level varies 
from community to community based on local resources and the incidence of 
tuberculosis reported in the community. In some communities, the BOH may 
contract with a home health care agency (e.g. a Visiting Nurse Association) to 
provide the required nursing case management services. The Division 
recommendations for case management by the local BOH nurse are based on those 
from the Centers for Disease Control and Prevention (CDC) and include, at a 
minimum, an initial case investigation and monthly visits. Because the complexity 
of care of patients is increasing due to multiple factors, at the same time resources 
are diminishing, it is becoming more difficult to get persons through an effective 
course of therapy. 
The TSA nurse's primary goal is to follow the case until discharged from the Case 
Registry for one of the following reasons: 1) the suspected case is determined not 
to have tuberculosis, 2) the person completes an appropriate and effective course 
of treatment, 3) the person moves to Boston or out of state, dies, or is completely 
lost to follow-up. Persons who move to Boston are referred to the Boston Public 
Health Commission TB Program for follow-up; persons moving out of state are 
referred to the relevant country or state health department TB control program. 
The TSA nurses work collaboratively with local nurses to determine the level of 
involvement and intensity of follow-up measures needed with patients to ensure 
adherence to therapy. Possible interventions include the assignment of an outreach 
educator (ORE) for weekly to monthly home visits, twice or thrice DOT, voluntary 
hospitalization, and compulsory (involuntary) hospitalization. The TSA nurses also 
advise local nurses on the appropriate contacts to screen and the evaluation and 
referral of patients. 
2. Direct Case Management 
All persons with confirmed and clinically suspected tuberculosis shall have a nurse 
designated by the local BOH as the direct case manager who will work in 
consultation with the regional TSA nurse, as necessary, to manage persons with 
confirmed or clinically suspected tuberculosis. This case management is required 
regardless of the source of health care (public or private) and the ability to pay for 
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services or medications.2  Utilization of a nursing case management model at the 
local level in the follow-up of tuberculosis patients provides a framework within 
which to deliver quality-nursing care and effect positive outcomes. 
Consultation available to local nurses by the TSA nurses assists the local nurse to 
implement a care plan, which is individualized and specific and will enable the 
patient to complete an effective course of treatment in the shortest time possible, 
while taking into consideration the resources available in the community. The 
Division employs several community ORE targeted to specific higher-risk 
communities or populations who work under the supervision of the TSA nurses and 
the Assistant Director of Patient Management Services. This process should result 
in continuous quality improvement through more frequent monitoring to ensure that 
the patient is following the care plan. 
B. The Case Management Process: 
A comprehensive nursing assessment is performed by the BOH-designated direct 
case manager from the perspective of the patient's personal and psychosocial 
needs, to identify factors which may affect adherence, access to appropriate health 
care, and barriers to care. Assessment of the patient's clinical status, including the 
degree of infectiousness, risk factors for drug resistance, nonadherence, and/or HIV 
infection helps the nurse develop an individualized nursing care plan, and implement 
therapeutic interventions, using the least restrictive measures appropriate for the 
patient. Not any one intervention will be appropriate for all patients, and measures 
that are more restrictive may be necessary for some patients. These interventions 
may need to be changed and priorities re-assessed over time, as the patient's 
health status or lifestyle changes. 
2Commonwealth of Massachusetts Regulations, Standards for Management of Tuberculosis Outside 
Hospitals, CMR 365:000. 
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II. CASE MANAGEMENT STANDARDS OF CARE 
Standards of Care: Standards of care and expected outcomes for the management 
of clinically suspected and confirmed cases of tuberculosis and their contacts 
include the following: 
Suspected/Confirmed Cases of Tuberculosis: 
1. The diagnosing health care provider reports potential cases to the Department of 
Public Health, Division of Tuberculosis Prevention and Control within 24 
working hours after suspecting the diagnosis and the Division reports it to the 
local health department/Board of Health (BOH) within 24 working hours. 
2. The local BOH designates a registered nurse as the direct case manager who will 
work in collaboration with the TSA nurse to manage the suspect/case until 
closed to supervision.3  This direct case manager may work for the BOH or 
other community health nursing agency contracted for public health nursing 
services by the BOH. 
3. The direct case manager conducts an initial nursing assessment (case 
investigation) within three working days after the BOH is notified of the 
potential case; the optimal standard is an assessment in the hospital and 
patient's home environment, accompanied by an outreach educator, when 
appropriate. 
4. The direct case manager initiates an individualized nursing care plan and further 
develops it with input and approval of the case management team. The care 
plan includes a medical treatment plan that is in accordance with the American 
Thoracic Society’s standards for care. 
5. For patients in a health care facility, discharge planning is done in collaboration 
with the BOH and the Division of Tuberculosis Prevention and Control. 
6. The direct case manager performs a monthly nursing assessment at the patient’s 
home, clinic, office, or other mutually agreed upon site. 
3 Closed to supervision: Patient completes an adequate and effective course of tuberculosis therapy; 
moves out of the community; or tuberculosis is ruled out as the diagnosis. 
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Contacts: 
7.	 The direct case manager initiates the contact investigation within three working 
days of notification of the potential case, ideally coinciding with the initial case 
assessment. The direct case manager begins the contact investigation report 
and sends it to the regional TSA nurse. 
8.	 Evaluation of identified contacts includes a Mantoux tuberculin skin test 
(Mantoux technique) and referral for a medical evaluation, including a chest 
radiograph when indicated. 
9.	 Contacts under five years of age are considered for a course of treatment of 
latent TB infection, regardless of the skin test result. 
10. Immunosuppressed contacts are considered for a course of treatment of latent 
TB infection, regardless of the skin test result. 
11. The direct case manager re-tests contacts with an initial negative skin in 8 - 12 
weeks. Complete contact investigation report will be completed and send to 
the regional TSA nurse. 
Source Case Investigations: 
12. Perform a source case investigation on children under one year of age who 
have a positive tuberculin skin test. 
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III. TUBERCULOSIS NURSING CASE MANAGEMENT PROTOCOLS 
Case Reporting: Report confirmed and clinically suspected cases to the 
Massachusetts Department of Public Health, Division of Tuberculosis Prevention 
and Control within 24 hours of diagnosis on the TB Case/Suspect Reporting Form 
(# MDPH TB07) or by telephone to the 24-hour toll-free reporting line (1-888-
MASS-MTB). The Division sends a copy of the report form to the local health 
department within 24 hours. The Division immediately telephones the local health 
department for high-priority reports needing immediate follow-up. 
Nursing Case Management Model: The local Board of Health (BOH)/Health 
Department designates a nurse as the direct case manager. The Tuberculosis 
Surveillance Area Nurse (TSA) is the indirect case manager, coordinating care with 
other team members. A case management model uses individual approaches and 
tools to reach the desired outcomes rather than one standard approach for all 
patients. Members of the case management team include the patient, the direct 
case manager, the TSA nurse, the community outreach educator (ORE), and the 
physician; others may be brought into the team as needed for an individual case, 
such as a social worker, the clergy, etc. 
A. Initial Patient Assessment: 
1. Initial Case Investigation 
Conduct a case investigation on every confirmed or clinically suspected case of 
TB reported to the health department, including patients cared for by private 
providers. 
Objectives of case investigation: 
1. To establish rapport and trust with the patient. 
2. To collect data for the nursing assessment including demographic, medical, 
environmental, economic and social factors that may influence adherence to 
the prescribed treatment plan or pose barriers to accessing care. 
3. To determine the patient's potential to transmit the TB organism to others 
and to determine the risk to contacts based on the duration and location of 
potential exposures. 
4. To identify potentially exposed contacts. 
5. To provide education about tuberculosis to the patient and/or family. 
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Preparation for interview: 
Before interviewing the patient: 1) contact the physician to be sure the patient has 
been informed of the diagnosis and what the physician has told the patient; and 2) 
obtain clinical information regarding skin test results, chest x-ray, laboratory test 
results, particularly sputum smears and cultures, and other diagnostic test results. 
Interview: 
•	 Within three working days, the direct case manager performs the case 
investigation, including the interview (with an ORE as appropriate). 
•	 The initial interview includes a face-to-face encounter and is optimally done 
in the patient's home environment and/or hospital, but may occasionally be 
done at the board of health office. 
• During the interview, the nurse provides education in a culturally and 
linguistically competent manner on the following: 
 ¾	diagnosis; transmission; the prevention of TB transmission to others; 
medication administration; the effects of inadequately treated TB; the 
importance of completing the prescribed course of treatment (including 
keeping all appointments); the consequences to the individual if he or 
she is unwilling to adhere to the treatment plan; and the health care 
system. 
• During the interview, the nurse: 
 ¾	collects information including demographic, medical, environmental, 
economic and social factors that may influence adherence to the 
prescribed treatment plan or pose barriers to accessing care; 
• Begins identifying potentially exposed contacts; 
•	 Performs an HIV risk assessment for patients with unknown HIV status (see 
Appendix for sample HIV Risk Assessment tool – form # MDPH - TB14). 
• Refer patients with risk(s) for HIV counseling and testing. 
•	 After the investigation is completed, the direct case manager completes the 
TB history form (form # MDPH – TB04B) and sends it to the TSA nurse. 
2. Contact Investigation 
The goal of a contact investigation is to identify contacts who will benefit from 
a course of treatment of latent TB infection. The direct case manager conducts 
an investigation on all persons with pulmonary or laryngeal TB. 
Objectives of contact investigation: 
1. To identify persons who have been exposed to the presenting infectious case 
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and who, therefore, are at greater risk of developing tuberculosis infection and 
disease than is the general population. 
2. To perform appropriate testing of identified contacts in a systematic fashion. 
3. To ensure access to medical evaluation and treatment of latent TB infection as 
appropriate for these contacts. 
4. When possible, to identify the source of tuberculosis disease transmission, 
particularly when the presenting case is a child. 
5. To identify environmental factors that may be contributing to the transmission of 
tuberculosis. 
6. To ensure medical evaluation, treatment, and follow-up of any additional cases 
of active tuberculosis identified during the contact investigation. 
Contact investigation procedure: 
•	 Use Concentric Circle Analysis theory to set limits and establish priorities for 
conducting the contact investigation according to the level of exposure. 
•	 Test close contacts with a tuberculin skin test using the Mantoux technique 
within 7 working days after the presenting case is clinically 
suspected/diagnosed. 
•	 Obtain nursing histories of contacts to identify risk factors for progression to 
TB disease, such as immunosuppression, history of previous infection and/or 
therapy, and/or risk factors for drug resistance. 
•	 Discuss the need to test contacts at worksites, schools, and other institutions 
with the TSA nurse before notifying the employer, school, or other institution; 
the Division will provide written testing recommendations according to the 
Division’s Worksite/School/Institution Contact Investigation Protocol. 
•	 For close contacts located in another community, notify that BOH of the need 
to test the contacts and return the results to you for your records. 
•	 If there is evidence that transmission occurred among the contacts tested (the 
inner circle), then expand the testing to the next circle of contacts. 
•	 Within 2 weeks, refer for a medical evaluation all infected contacts and the 
following non-infected contacts: children under five years of age, adolescents 
and immunosuppressed persons 
•	 Initiate the Contact Report (Epidemiologic Report on a Tuberculosis Case form # 
MDPH-TB03) and send the first copy with the results of the first round of 
testing and medical evaluations to the TSA nurse within thirty days. 
• Re-test non-infected contacts in eight to twelve weeks. 
• Send the final copy of the Contact Report with results of the second round of 
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testing and medical evaluations to the TSA nurse within three months. 
•	 Follow up with the physician to verify that infected contacts were offered 
treatment for latent TB infection, regardless of age. 
•	 Follow up with the physician to verify that contacts who are under five years of 
age, adolescents, or immunosuppressed persons were offered treatment for 
latent TB infection, regardless of skin test results. 
B. Nursing Care Plan: 
The direct case manager initiates the plan and further develops it in 
collaboration with the TSA nurse and other case management team members. 
Objective of the nursing care plan: 
To identify interventions that use the least restrictive measures appropriate for 
the patient and protect the health of the public. 
Care plan process: 
•	 Formulate the nursing diagnoses from the data collected by various team 
members, including the nurse's assessment, the outreach educator's patient 
interview, and the medical evaluation. 
•	 The team discusses appropriate strategies and tools needed to assist the 
patient to complete therapy. 
• The team discusses the need for ORE involvement. 
•	 The plan includes specific approaches and strategies and identifies the 
person(s) responsible for implementation; the integration of cultural and ethnic 
beliefs and health practices; and appropriate regimens based on drug 
susceptibility data. 
• The team accepts the patient care plan. 
1. Treatment Plan 
Note:  Medical treatment is in accordance with the American Thoracic society's 
recommended treatment regimens. A copy of these recommendations is 
available from the Division and consultation is available through the TSA nurse 
or the Division's TB Control Officer. (See Appendix for medication dosage chart 
- MDPH TB15). 
Treatment Principles: 
1. All patients in Massachusetts with unknown sensitivities are to start on four 
drugs (usually isoniazid, rifampin, pyrazinamide, and ethambutol). 
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2. To obtain optimal blood levels, each medication is usually taken in a single daily 
dose, not split into multiple doses. (Second-line drugs are usually split into 
multiple doses.) 
3. Patients who are to be on self-administered medications are to be placed on 
fixed-dose combination pills (rifater initially, and rifamate for the continuation 
phase). 
4. Patients who receive directly observed therapy (DOT) could be placed on twice 
or thrice weekly intermittent therapy after two weeks of daily therapy. 
2. Discharge Plan 
Any healthcare institution or correctional facility which plans to discharge a person 
with confirmed or suspected tuberculosis into the community needs to develop a 
discharge plan in collaboration with the state TB Division and local health 
department. 
•	 Discharge planning begins upon admission of the person with confirmed or 
clinically suspected tuberculosis. 
•	 The institution promptly reports the person to the state health department; the 
TSA nurse notifies and works with the direct case manager to develop an 
appropriate discharge plan. 
•	 Pre-discharge consultation is required and includes the direct case manager, the 
hospital discharge planner, and other appropriate team members. Good 
communication is key to developing an appropriate outpatient treatment plan. 
•	 Hospital providers and the direct case manager participate in and agree upon 
the discharge plan. Assess patient for any risk factors for non-adherence. 
Include interventions for appropriate medical, nursing, and community follow-
up. 
•	 Infectious persons must not be discharged to a home or other environment until 
the risk of ongoing transmission to vulnerable persons (e.g. infants, young 
children or immunosuppressed persons) is minimized. 
•	 A pre-discharge home visit by the direct case manager is strongly 
recommended to evaluate the home environment and potential risk to others. 
•	 Arrange for the patient to have enough TB medications, in hand, until his/her 
next medical appointment. Prescriptions alone are usually inadequate for the 
new TB patient (pharmacies may not have drugs, or there may be linguistic and 
economic barriers). 
• Make follow-up appointments prior to discharge. 
October 2001 17 
C. Implementation: 
Note:  The next section (Treatment Delivery Protocols) provides specific 
guidelines for the implementation of the patient care plan, including guidelines 
for the use of self-administered therapy and directly observed therapy. 
Objectives: 
1. To implement and coordinate the interventions identified in the plan of care. 
2. To implement the plan in a safe and appropriate manner consistent with public 
health laws and regulations. 
3. To deliver care by linking the patient with other appropriate service providers. 
4. To ensure appropriate delegation of interventions that are to be implemented by 
other team members. 
Implementation of the Medical Plan: 
•	 A physician's order is required to initiate treatment. Drug order changes must 
be obtained promptly to prevent any interruption in therapy. The direct case 
manager needs to contact the physician if the patient is started on less than 
four anti-tuberculous drugs. 
3. Outreach Involvement 
Availability and assignment of community outreach educators: The Division 
employs several community ORE targeted to specific high-risk communities or 
populations who work under the supervision of the TSA nurses. The Refugee and 
Immigrant Health Program (RIHP) also employs OREs who work with refugee and 
immigrant populations, particularly persons from Southeast Asia, the former Soviet 
Union, and other countries with new refugee populations. 
•	 The direct case manager notifies the TSA nurse when the assistance of an ORE 
is needed. Based on availability and priority, the TSA nurse may assign an ORE. 
•	 The TSA nurse clinically supervises the Division’s OREs with clinical backup of 
the ORE provided by the Assistant Director for Patient Management services or 
RIHP Coordinator. 
•	 The TSA nurse will assign an ORE to every new suspect/case, when feasible, 
within 3 working days of notification to visit with the patient and conduct an 
outreach educator interview. 
•	 The TSA nurse will notify the RIHP for all refugees and immigrants from 
populations served by the RIHP. 
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•	 Optimally, the ORE does the initial interview in a joint visit with the direct case 
manager during the initial case investigation. 
•	 The ORE is responsible for documenting and reporting any patient complaints or 
change in the patient’s condition to the direct case manager. 
Priorities for Outreach Educator Assignments: The following persons are the 
highest priority for the assignment of an ORE: 
Suspects/Cases: 
• requiring DOT 
• admitted to the Tuberculosis Treatment Unit at Lemuel Shattuck Hospital 
• with drug resistance, especially multidrug resistant tuberculosis 
• with a history of or risk factors for non-adherence, including previous TB 
• who are class A/B immigrant arrivals 
• under eighteen years of age 
Contacts on Treatment for latent TB infection: 
• exposed to multidrug resistant tuberculosis cases 
• under eighteen years of age, particularly under five years 
Although these groups are the highest priority, the following persons on treatment 
for latent TB infection may also be a priority for the assignment of an ORE: 
•	 refugee/immigrant arrivals (within 5 years) to the United States from high 
prevalence countries 
• children, particularly under 5 years of age 
• persons discharged from a correctional institution 
• immunosuppressed persons 
4. Referrals for Other Community Resources as Needed 
•	 Link the patient with other appropriate service providers to address the total 
needs of the patient (i.e. fuel assistance, social services, counseling). 
D. Evaluation: 
The direct case manager evaluates the patient monthly in a face-to-face 
encounter for clinical response, adherence to therapy, and possible adverse 
reactions to the medications. 
Objectives: 
1. To re-evaluate the patient care plan and revise as necessary. 
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2. To evaluate the patient's clinical response to therapy and prevent the 
development of drug resistance, adverse reactions, or further morbidity. 
1. Monthly Evaluation by the Direct Case Manager: 
•	 Assess for a response to therapy as indicated by clinical improvement and 
sputum conversion. Collect sputum weekly until conversion; induce sputum if 
necessary. A physician’s order is not needed to collect sputum. 
•	 Assess for any signs of adverse drug reactions through patient interviews and 
periodic laboratory tests (liver function tests, basic audiometry, visual acuity 
screening, etc.). 
•	 At each patient encounter, check for adherence to the treatment plan through 
patient interviews. 
•	 For persons on self-administered therapy, test the urine for INH metabolites at 
each patient encounter and observe urine for the presence of rifampin. 
•	 When an ORE is assigned to the patient, the direct case manager and the ORE 
need to communicate on a regular basis regarding the patient’s progress. 
• Contact the patient’s physician to monitor the patient’s progress. 
•	 Consult with the case management team regarding the use of more restrictive 
measures if patient is non-adherent with the treatment plan, such as the use of 
incentives and enablers, ORE involvement, directly observed therapy, voluntary 
hospitalization, and compulsory (involuntary) hospitalization. This consultation 
may result in revising the plan. 
•	 Complete a TB clinic Case/Suspect Follow Up Form (form # MDPH – TB05) or 
nursing notes for each encounter. Document assessment of clinical status and 
adverse reactions, all teaching and instructions to the patient, and any changes 
to the treatment plan. 
•	 A Drug-O-Gram (form # MDPH – TB09) can be used to evaluate the adequacy 
of the treatment regimen, especially in drug resistant cases or cases whose 
treatment requires a change from the standard drug regimen. 
Note:  Patients who have interrupted therapy for more than two consecutive 
weeks may need to have their length of therapy re-evaluated and may need to 
restart treatment from the beginning after consultation with the physician. 
2. Division of Tuberculosis Prevention and Control Evaluation Plan: 
Division staff reviews newly confirmed and suspected cases and contact 
investigations initially at monthly review conferences. Division staff 
retrospectively reviews confirmed cases at six-month intervals until the end of 
treatment. 
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IV. TREATMENT DELIVERY PROTOCOLS 
Treatment Standard of Care: Evaluate every suspected case of tuberculosis for the 
need for directly observed therapy (DOT) based on an assessment of risk factors 
for non-adherence. For patients on therapy for TB disease without any known risk 
factors for nonadherence, the Division recommends self-administered therapy, 
using fixed-dose combination pills (rifater for the initial phase and rifamate for the 
continuation phase) as the standard of care. 
Completion of adequate therapy is the responsibility of the case management team. 
The method of treatment delivery (i.e. self-administered or directly observed 
therapy) is the team’s decision. 
Candidates for Directly Observed Therapy: The following persons are to receive 
DOT: 
• patients with a prior history of non-adherence/incomplete TB treatment; 
• patients with a previous episode of TB; 
•	 patients with drug resistant tuberculosis disease, especially resistance to two or 
more drugs; 
• patients unwilling, or unable, to follow prescribed treatment regimens; 
•	 patients discharged from the Tuberculosis Treatment Unit (TTU) at Lemuel 
Shattuck Hospital (LSH) on treatment; 
• children under eighteen years of age with tuberculosis disease; 
•	 patients with a history in the past year of: substance abuse, homelessness or 
incarceration; 
• patients with a recent history of mental illness; 
•	 contacts to multi-drug resistant cases who are on treatment for latent TB 
infection; 
• contacts under five years of age who are on treatment for latent TB infection. 
A. Guidelines for Self Administered Therapy: 
Self-administered therapy is the ingestion of prescribed anti-tuberculosis 
medication by the patient. 
1. Initiate Treatment 
•	 Self-administered therapy is best done on a daily basis; the use of fixed-dose 
combination drugs can only be done daily as the dosage is not amenable to 
twice/thrice weekly administration. A specific physician’s order is required to 
initiate fixed-dose combination pills. 
• Give the patient only a one-month supply of medication. 
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•	 Consider incentives, enablers, the use of community outreach educators and/or 
a patient contract (see sample letter in forms section) to assist the patient 
through treatment. 
•	 Consider providing a pillbox to assist the patient in taking the medications 
correctly. If they are used, consult the pharmacist to ensure appropriate 
labeling of the box. An alternative is for the health care worker to oversee the 
patient pouring the medications into the box compartments. 
2. Educate Patient 
•	 Provide appropriate written instructions and oral education to the patient 
regarding his/her treatment and follow-up in a culturally and linguistically 
competent manner. 
• Reinforce education at every encounter with the patient. 
3. Evaluation 
The direct case manager evaluates the patient monthly in a face-to-face 
encounter for clinical response, adherence to therapy, and possible adverse 
reactions to the medications. 
Medication Monitoring: 
•	 Assess for any signs of adverse drug reactions through patient interviews and 
periodic tests (liver function tests, basic audiometry, vision disturbances, etc.). 
•	 Tell patient to discontinue medications and report the symptoms when there 
are indications of adverse reactions. Consult with the physician immediately. 
Clinical Response to Therapy: 
•	 Assess for response to therapy as indicated by clinical improvement and 
sputum conversion. Collect sputum weekly until conversion; induce sputum 
collection, if necessary. A physician’s order is not needed to collect sputum. 
• Consult with the physician if patient fails to improve. 
Adherence to Therapy: 
•	 At each patient encounter, check for adherence to the treatment plan through 
patient interviews and test the urine for INH metabolites and observe the urine 
for the presence of rifampin. 
•	 If the patient fails to keep an appointment, attempt contact by phone. If the 
patient cannot be reached by phone, make a home visit within 24 hours. 
• If nonadherence is suspected or patient cannot be located, notify TSA nurse. 
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B. Guidelines for Directly Observed Therapy (Dot): 
Directly Observed Therapy (DOT) is the direct observation, by a health care 
provider or other designated responsible person, of the ingestion of prescribed 
anti-tuberculosis medication by the patient. Observation by a family member is 
not considered DOT. 
Directly Observed Therapy (DOT) Procedure: 
•	 The direct case manager implements DOT with input from other members of 
the case management team (physician, ORE, TSA Nurse/RIHP). The direct case 
manager advises the patient that a health care worker will observe each dose 
of medication. Depending on resources, an ORE may be available to assist the 
direct case manager in providing DOT. 
•	 DOT may be done exclusively by the direct case manager or may be a shared 
responsibility between the direct case manager and an ORE. 
• A physician’s order is not required to initiate daily DOT. 
•	 DOT is best done on a twice weekly or thrice weekly intermittent dosing 
routine. An intermittent dosing regimen does require a physician’s orders. 
•	 For patients receiving DOT daily, allow the patient to self-administer 
medications on the weekend (ensure that a weekend supply of medication is 
available), unless it appears the patient is unable or unwilling to take medication 
safely and reliably, in which case, arrangements for weekend DOT will be 
necessary. On Monday discuss the previous weekend’s self-administered 
therapy with the patient, test the urine for INH metabolites and observe the 
urine for the presence of rifampin and document adherence indicators. 
•	 Attempt to schedule a mutually agreeable time and place for DOT. Tailor the 
DOT site and time to meet the needs of the patient. Listen to and validate 
patient concerns regarding DOT. 
•	 Consider using a patient contract (see sample letter in forms section) and/or 
incentives. 
•	 If DOT is scheduled on-site at the clinic or health department, minimize the 
waiting time. 
•	 If the patient fails to keep an appointment, attempt phone contact. If the 
patient cannot be reached by phone, make a home visit within 24 hours. If 
unable to locate or if the patient misses one week of treatment, notify the TSA 
Nurse. Document indications of nonadherence (missed clinic/DOT appointment, 
not at home when nurse or ORE visits). 
•	 If DOT is scheduled at the patient’s home, leave the medications in the 
patient’s home. When the nurse/ORE arrives for DOT, if the patient states 
he/she already took the medications, or there is other evidence that the 
medication count is incorrect, consider keeping the medications at health 
department in the original medication bottles. The nurse/ORE picks up the 
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bottles from the health department before each visit to the patient. An 
alternative solution is to supply a locked box for the medications, which is left 
in the patient’s home (one key is kept by the direct case manager and one by 
the ORE). 
•	 If the patient is not available for DOT, do not leave the medications at the 
home. 
•	 Record each observed dose of medication on a medication sheet or the DOT 
Log (form # MDPH – TB11) 
•	 Document all teaching and instructions to the patient. Complete a TB clinic 
Follow Up Form (form # MDPH – TB05 or MDPH – TB06) or nursing notes for 
each encounter. 
•	 Periodically re-evaluate the need for continuation of DOT. Re-evaluation of the 
treatment delivery method may indicate a change to lesser or more restrictive 
measures. 
C. Guidelines for Long-term Hospitalization: 
Admission to the Tuberculosis Treatment Unit (TTU) is reserved for persons 
with confirmed or clinically suspected tuberculosis who cannot or should not be 
managed in the outpatient setting. The admission may be voluntary or 
involuntary. 
1. Voluntary hospitalization 
•	 Voluntary hospitalization is appropriate for persons with complex medical, 
psychosocial, and infection control management problems. 
•	 If patient agrees to a voluntary hospitalization, the direct case manager 
consults with the TTU Medical Director for admission and explains the TTU 
environment to the patient. 
2. Involuntary (compulsory) hospitalization 
•	 Involuntary hospitalization or confinement may be necessary when there is 
documented nonadherence to the prescribed treatment plan for tuberculosis, or 
the patient is unable to follow the treatment plan and the public’s health is 
threatened as a result. 
•	 Employ less restrictive measures before imposing measures that are more 
restrictive. 
•	 The direct case manager needs to document failed attempts at using least 
restrictive nursing interventions (DOT, incentives, and enablers). (See M.G.L. 
c.111, Section 94A for involuntary commitment procedures). 
•	 If the admission is involuntary, follow the procedures set forth in M.G.L. c.111, 
Sections 94A through 94C. Us less restrictive measures first, and give the 
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patient the opportunity for voluntary admission prior to involuntary admission. 
Guidelines for Treatment of Latent TB Infection: 
Priorities for Treatment of Latent TB Infection: 
The persons who benefit most from treatment of latent TB infection are those at 
highest risk of developing active disease once infected. Priorities for nursing case 
management of persons on treatment for latent TB infection are listed below: 
• contacts to multi-drug resistant tuberculosis cases; 
• children under five years of age who are close contacts; 
• infected close contacts (of a known or suspected infectious case of TB disease) 
• persons with Class A/B Immigrant status; 
• persons with an abnormal chest x-ray consistent with old inactive TB; 
• infected children under five years of age; 
• infected non-US born persons here less than five years; 
•	 persons with current or past history of substance abuse, mental illness, 
homelessness, or incarceration; 
• HIV infected persons; 
•	 persons with medical conditions that predispose them to active TB (i.e. insulin 
dependent diabetes mellitus, renal failure, gastrectomy, silicosis). 
1. Initiate Treatment of Latent TB Infection 
•	 Treatment of latent TB infection is best done on a daily basis; the use of twice-
weekly directly observed treatment of latent TB infection (DOPT) may be used 
for at-risk adults and children who cannot or will not reliably self-administer 
therapy. The priorities for DOPT are contacts under five years of age and 
contacts to multi-drug resistant TB cases (see Guidelines on Directly Observed 
Therapy for the procedure). 
•	 Give the patient only a one-month supply of medication (see below for two-
month regimen). 
•	 A pillbox may be used to assist the patient in taking the medications correctly. 
If a pillbox is used, consult the pharmacist to ensure appropriate labeling of the 
box. An alternative is for the health care worker to oversee the patient pouring 
the medications into the box compartments. 
2. Educate Patient 
•	 Provide appropriate written instructions and oral education to the patient 
regarding the medication and follow-up in a culturally and linguistically 
competent manner. 
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• Reinforce education at every encounter with the patient. 
3. Evaluation 
•	 Evaluate the patient monthly in a face-to-face encounter for adherence to 
therapy and possible adverse reactions to the medications (see below for two-
month regimen). 
•	 Assess for any signs of possible adverse drug reactions through patient 
interviews. Routine baseline and follow-up laboratory monitoring can be 
eliminated in most persons with latent TB infection, except for those with HIV 
infection, pregnant women (or those in the immediate postpartum period), 
persons with chronic liver disease or those who use alcohol regularly. 
•	 Tell patient to discontinue medications and report the symptoms when there 
are indications of adverse reactions. Early signs of hepatitis include anorexia 
and malaise. Consult with the physician. 
•	 If the patient develops symptoms of active disease while on treatment, 
immediately refer the patient for a medical evaluation. 
•	 At each patient encounter, check for adherence to the treatment plan through 
patient interviews, and test the urine for INH metabolites or rifampin. 
• If the patient fails to keep monthly appointments, attempt contact by letter or 
phone. 
 ¾ For low-risk individuals, after three failed clinic appointments, 
document efforts, and close out patient’s record. 
 ¾	For high-risk individuals, the use of other strategies may be needed to 
assist the patient through treatment, such as different regimens, 
incentives, enablers, or community outreach educators. 
•	 Completion of therapy is based on total number of doses administered – not on 
duration of therapy alone. 
•	 Complete nursing notes or a TB clinic Preventive Therapy Follow Up Form (form 
# MDPH – TB06) for each encounter. 
Two-month Regimen of Rifampin (RIF) and Pyrazinamide (PZA) 
•	 No more than a 2-weeks supply of RIF/PZA should be dispensed at a time to 
facilitate periodic clinical assessments. 
•	 Evaluate the patient at two, four and six weeks of treatment in a face-to-
face encounter for adherence to treatment, tolerance, and possible adverse 
reactions and at eight weeks to document completion of treatment. 
•	 At each encounter, instruct patients, in a language they understand, to stop 
taking RIF/PZA immediately and seek medical consultation if symptoms 
develop. 
• Document therapy completion on clinic Preventive Therapy Follow-Up form. 
•	 Completion of therapy with the RIF/PZA regimen is defined as taking 60 
doses of the prescribed medications within a three-month period. 
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Figure 1. CARE CONTINUUM 
least restrictive most restrictive 
self-administered DOT voluntary compulsory 
fixed-dose combination pills  hospitalization hospitalization 
<---------------------------------------monthly nursing visit---------------------------------> 
Least Restrictive Measures: Patients without any known risk factors for non-

adherence

Self-administered therapy/fixed-dose combination pills: The standard of care 

recommended by the Division is self-administered therapy, using fixed-dose 

combination pills - rifater or rifamate.

Monthly Nursing Evaluation

Use of Incentives and/or enablers. 

Educational materials as appropriate

Incentives/enablers as appropriate

Moderately Restrictive Measures: Patients with potential or demonstrated risk 
factors for non-adherence 
Outreach Educator Assignment: Patients on self-administered medications may 
need weekly home visits by an ORE in addition to the monthly nursing 
assessments. Adherence monitoring by the ORE includes pill counts, sputum 
collections, urine testing, and DOT. 
Directly Observed Therapy: Directly observed therapy (DOT) by the ORE and/or 
nurse, depending on resources and clinical status of patient. The nurse will 
encourage the physician to order twice/thrice weekly therapy when appropriate. 
Most Restrictive Measures: 
Voluntary Hospitalization: Voluntary hospitalization at the Tuberculosis Treatment 
Unit at Shattuck Hospital for clinical indications, such as infectiousness, which 
prohibits remaining in the community; adverse reactions to medications; failure to 
improve; acuity level of disease requiring hospitalization; or problems with impaired 
communication or mobility. 
Compulsory Hospitalization: Involuntary hospitalization due to continued 
demonstrated nonadherence to therapy. Less restrictive measures must be tried 
first and compliance with procedures required by State regulations. 
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V. CONTACT EVALUATION AND MANAGEMENT 
Theoretical Framework: Contact investigation or tracing identifies those persons 
who are at greatest risk of having been infected with TB by the index or presenting 
case and who are at high risk for progression to disease. Successful contact tracing 
requires skills in patient assessment, interviewing, counseling, and evaluation.4 
The Concentric Circle Approach is the standard method of investigation used for 
contact tracing. This method provides a systematic approach for setting limits and 
establishing priorities for testing based on the risk of tuberculosis transmission to 
the identified contacts. 
Analysis of the results of the contact investigation is important in determining the 
need for further testing based on the actual risk of tuberculosis transmission that 
has occurred. Use the Concentric Circle Analysis tool (see Figure 2) to calculate 
rates of actual transmission in contacts exposed to the index case in different 
settings. Rates of infection higher than expected in any of the settings indicate a 
need to expand the testing to the next circle of contacts with less exposure. 
Legal Authority: 105 CMR 365.200, section C.4 provides the legal authority for the 
investigation and reporting of contacts to the Massachusetts Division of 
Tuberculosis Prevention and Control. 
A. Transmission Risk Assessment: 
Identifying the appropriate contacts to test can be a difficult process as there are 
many variables to consider that may affect your decisions. Begin by assessing the 
infectiousness and potential for transmission of each suspected and confirmed case 
of tuberculosis when initiating the contact investigation. Collect information 
regarding person (characteristics of the suspect case and contacts), place (potential 
exposure sites and their characteristics), and time (duration of exposure) factors to 
determine the priority and extent of the contact investigation. Evidence that 
transmission has occurred will impact your decisions regarding who to test or when 
to expand the limits of the contact investigation. 
1. Person Factors 
Person factors include clinical characteristics of the suspect case that indicate the 
case’s infectiousness and potential to transmit infection, as well as clinical factors 
associated with the contact’s immune response - the contact’s probability of 
becoming infected. Cases with a high likelihood of transmission are those who 
have laryngeal or pulmonary disease, a productive cough, an acid-fast bacteria 
4 Boutotte, J. and Etkind, S. “Community-Based Strategies for Tuberculosis Control” in 
Tuberculosis: A Sourcebook for Nursing Practice,” Cohen, F., and Durham, J., Eds. Springer 
Publishing Co., NYC. pp. 180-181. 
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(AFB)-positive sputum smear (spontaneous specimen), lung cavitation, and who are 
not on anti-tuberculous medications. Those with a lower probability of transmission 
have extrapulmonary disease, AFB-negative sputum smears, no lung cavities, are 
not coughing, or have been on anti-tuberculous medications for at least two weeks. 
Factors to be considered in evaluating a contact’s susceptibility include immune 
status, especially immunosuppression due to HIV disease, and the possibility of 
previous infection. 
2. Place Factors 
Place factors include the environment of the potential exposures. Evaluate the 
potential for exposure in each of the three sections of the Concentric Circle: home, 
work or school, and leisure activities (see Figure 2). In some circumstances, 
exposure outside the home may be as high or higher than in the home, and contact 
testing will need to be done there, independent of the contact investigation results 
within the home. 
Place factors also include the characteristics of the physical environment, such as 
the size of rooms (volume of air), ventilation, number of persons in the room and 
presence or absence of sunlight or ultraviolet lighting. 
3. Time Factors 
Time factors include the potential duration and frequency of exposure of the 
contacts to the case. Prolonged exposure is normally needed for transmission to 
occur. However, the length of exposure needed for a case to transmit the bacteria 
to a contact is impacted by the infectiousness of the case, the contact’s immune 
system, and the environmental characteristics. To determine the length of possible 
exposure, consider the case’s date of onset of symptoms, especially the cough. 
The highest potential for transmission to occur is from this time until the case is on 
adequate treatment for at least two weeks, is clinically improving, and has three 
negative sputum smears. 
4. Evidence of Transmission 
To determine if transmission has occurred consider the level of infection (number of 
infected contacts without a known history of a positive tuberculin skin test), 
infection in young children, documented skin test conversions, and secondary 
cases of disease. If there is evidence of transmission, you may need to expand the 
circle of contacts to test until there is no further indication of exposure. 
B. Priorities for Contact Investigation: 
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As discussed in section ‘A’, contact investigations are prioritized according to the 
characteristics of the (confirmed or suspected) TB case, the characteristics of the 
contact, the environment, and the duration of exposure. Contacts to individuals 
who have sputum smear-positive pulmonary or laryngeal tuberculosis are at highest 
risk to become infected with M. tuberculosis. Evaluate a contact if the known or 
suspected case has the following characteristics: 
1) sputum or laryngeal specimen smear-positive for AFB 
2) negative sputum or laryngeal AFB smear, but positive M. tuberculosis culture 
3) other respiratory specimens AFB smear or culture-positive 
4) negative cultures for M. tuberculosis, but cavitary chest x-ray 5 
5)	 definite clinical evidence of active pulmonary TB and actively coughing, but 
AFB smears and/or cultures were not obtained prior to the initiation of anti-
tuberculous treatment * 
Contact investigations are not recommended for extra-pulmonary cases. A source 
case investigation may be indicated for a child less than five years of age 
diagnosed with extra-pulmonary tuberculosis disease to seek the infectious source 
patient who infected the child. 
C. Evaluation and Management of Contacts: 
1. Symptom Review 
Contacts with tuberculosis symptoms have priority over all other contacts. 
•	 Immediately evaluate for TB disease contacts who have symptoms consistent 
with tuberculosis: obtain a chest x-ray and sputum specimen for smear and 
culture and administer a tuberculin skin test. If indicated, evaluate for extra-
pulmonary sites of disease. 
•	 Classify and report contacts with tuberculosis symptoms as TB suspects, 
regardless of the chest x-ray findings and tuberculin skin test reactions. 
2. Initial Tuberculin Skin Test and Follow Up 
Test all close contacts of an individual who has an AFB-positive sputum smear or a 
positive M. tuberculosis culture for tuberculosis infection with a tuberculin skin test 
(TST), unless they have documentation of a previous positive TST reaction. All 
close contacts identified are to be listed on the Contact Report (Epidemiologic 
Report on a Tuberculosis Case form # MDPH–TB03). 
5Contact investigation for persons with negative or unknown sputum cultures is not routinely 
recommended, provided there are no other relevant clinical or exposure factors, indicating a need for 
testing. 
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Contacts with a documented previous positive reaction need a chest x-ray only if 
they have symptoms suggestive of tuberculosis or are immunosuppressed or have 
other medical risk factors. 
•	 If the reaction to the initial TST is positive (> 5 mm), the contact needs a 
chest x-ray. 
~ If the chest x-ray is abnormal, immediately evaluate the contact for 
tuberculosis disease. 
~ If the chest x-ray is normal, evaluate the contact for treatment of latent TB 
infection. 
•	 In some instances, an individual may state that he or she has a past positive 
TST reaction. If it is not possible to verify this information, you may repeat the 
TST (unless the person describes a “very large” reaction the size of a quarter or 
larger to a previous TST). 
•	 Complete the first copy of the Contact Report (Epidemiologic Report on a 
Tuberculosis Case form # MDPH–TB03) and send to the regional TSA office. 
3. Repeat Tuberculin Test and Follow Up 
•	 If the reaction to the initial TST is negative (< 5mm), a repeat TST should be 
given eight to twelve weeks after the contact’s last exposure to the case, while 
the case was infectious. 
~ During the window period between the two TSTs, the following contacts 
should have a chest x-ray to rule out tuberculosis disease and start 
preventive treatment, even if the TST is negative (Window Prophylaxis): 
1) contacts under five years of age; 
2) contacts between five and fifteen years of age, at the physician’s discretion; 
3) contacts who are HIV seropositive or otherwise immunosuppressed; 
4) contacts with known risk factors for HIV infection who decline HIV testing. 
•	 If the initial TST for a contact is not done until eight weeks after the contact’s 
last exposure to the case (while infectious), and the reaction is negative (< 
5mm), a repeat TST is not indicated. 
•	 If the reaction to the repeat TST is positive (> 5 mm), the contact needs a 
chest x-ray (if one has not already been done). 
~ If the chest x-ray is abnormal, immediately evaluate the contact for 
tuberculosis disease. 
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~ If the chest x-ray is normal, evaluate the contact for treatment of latent TB 
infection. 
•	 If the reaction to the repeat TST is negative (< 5mm) and the individual is no 
longer in close contact with an infectious patient: 
~ For immunocompetent contacts (including children), no follow-up is 
necessary. Discontinue prophylaxis treatment, if started initially. 
~ For most close contacts who are HIV seropositive or have known risk factors 
for HIV infection, but decline HIV testing, a full course of treatment of latent 
TB infection is indicated, regardless of the TST reaction. Anergy testing has 
no role in the evaluation of contacts. 
•	 If the reaction to the repeat TST is negative (< 5mm) and the individual 
remains in close contact with an infectious patient, continue treatment if he or 
she: 
1) is under five years of age; 
2) is between the ages of five and fifteen, at the physician’s discretion; 
3) is HIV seropositive or otherwise immunosuppressed; or 
4) has known risk factors for HIV infection, but declines HIV testing. 
~ Repeat the TST every three months for uninfected contacts who remain in 
close contact with an infectious case. 
•	 Complete the second copy of the Contact Report (Epidemiologic Report on a 
Tuberculosis Case form # MDPH–TB03) and send to the regional TSA office. 
A sample letter is provided in the Forms section that can be used to obtain 
contact testing and follow-up data done by private providers. 
4. Contact Evaluation for Patients whose Cultures Convert Back to Positive 
In some instances, a tuberculosis patient’s cultures may convert to negative and 
then become positive again. This may happen if a patient is lost to follow-up and 
discontinues his or her medication before completing treatment, or if treatment was 
not adequate. 
•	 If the patient is found after a treatment lapse of three months or longer and his 
or her cultures have become positive again, or if the patient relapses while on 
treatment after becoming culture negative, a second window period needs to 
be defined and the patient needs to be re-interviewed. 
October 2001 33 
~ Re-evaluate contacts identified during the initial investigation if they were 
exposed again. 
~ Test and evaluate any new contacts identified. 
D. Special Considerations for Infant and Child Contacts: 
Infants and children under five years of age who live in the same household as an 
infectious tuberculosis patient may need to be removed from the home setting (or 
hospitalize the patient) until one of the following conditions is met: 
•	 The infectious patient has been on appropriate effective tuberculosis 
chemotherapy for at least two weeks and has demonstrated a clinical response 
to treatment (e.g., decreased cough and fever, resolving lung infiltrates, a 
consistent decrease in the numbers of organisms on sputum AFB smears) or 
has three consecutive negative sputum smears, at least 24 hours apart.6 
•	 The child has started treatment of latent TB infection (including window 
prophylaxis). 
1. Initial Tuberculin Skin Test and Chest X-ray for Infants 
All infant contacts need to receive an initial TST and both a posterior-anterior and a 
lateral chest x-ray. 
•	 If the chest x-rays are normal, start the infant on window prophylaxis treatment 
of latent TB infection, even if the TST reaction is negative (< 5mm). Isoniazid 
is used for infant contacts of patients with isoniazid-susceptible tuberculosis 
disease; rifampin can be used for contacts of patients with isoniazid-resistant 
but rifampin-susceptible tuberculosis disease. Consider multi-drug preventive 
treatment with medications other than isoniazid and for infant contacts to 
patients with multi-drug resistant disease (resistant to at least isoniazid and 
rifampin). 
~ Breast-feeding is not contraindicated when the mother is being treated for 
latent TB infection, but the infant should receive supplemental pyridoxine. 
~ The amount of isoniazid provided by breast milk is inadequate for treatment 
of the infant. 
~ If the reaction to the initial TST was positive (> 5 mm), the infant needs to 
complete a full course (9 months) of treatment of latent TB infection. 
6Department of Public Health, Reportable Diseases and Isolation and Quarantine Requirements, CMR 
105. 
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•	 If the chest x-rays show hilar adenopathy (with or without a pulmonary 
infiltrate), refer the infant for diagnosis and treatment, even if the TST reaction 
is negative (< 5 mm). Consultation with a pediatric pulmonologist may be 
indicated to evaluate the cause of hilar and/or mediastinal lymphadenopathy. 
Early morning gastric aspirates may be indicated to obtain specimens for 
diagnostic purposes. 
2. Repeat Tuberculin Skin Test and Chest X-ray for Infants 
All infant contacts with a negative reaction to the initial TST should have a repeat 
TST at three to four months of age and again at six months of age. (Infants 
younger than six months old may be anergic.) 
•	 If the reaction to the repeat TST converts to positive (> 5 mm), the infant 
needs both a posterior-anterior and a lateral chest x-ray. If the chest x-rays are 
normal, continue the treatment for a total of 9 months. 
~ If the chest x-rays show hilar adenopathy (with or without a pulmonary 
infiltrate), refer the infant for diagnosis and treatment. Early morning gastric 
aspirates may be indicated to obtain specimens for diagnostic purposes. 
•	 If the reaction to the repeat TST is negative (< 5 mm) and the chest x-rays are 
normal, treatment of LBTI may be discontinued if the exposure has ended (the 
source case is on anti-tuberculosis treatment and has consistently negative 
tuberculosis cultures). If the contact is younger than six months old, continue 
treatment of latent TB infection until six months of age because an infant’s 
immune system is not fully developed and may not mount a response to the 
TST. 
Source Case Investigation 
The Massachusetts Division of Tuberculosis Prevention and Control recommends 
that a source case investigation be done for all children under 1 year of age found 
to have TB infection and who have not been identified as a contact to a known 
case of tuberculosis (see Appendix MDPH TB16 for policy and procedure). The 
possible source patient is usually an adult in the home, or an adult with whom the 
child spends significant periods of time (e.g., friends, relatives, baby sitters, 
daycare personnel, etc.) 
Possible Source Patient who is Symptomatic 
Promptly evaluate for disease any possible source patient who has symptoms 
suggestive of tuberculosis, by obtaining a chest x-ray, collecting three consecutive 
daily sputum samples for AFB smear and culture, and administering a TST. 
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 Figure 2 
CONCENTRIC CIRCLE ANALYSIS 
“Casual” 
# _____ 
% Infected ______ 
“Close” 
# _____ 
% Infected _____ 
“Casual” “Close” Index “Close” “Casual” 
# ____ # ____ # ____ # ____ 
% Infected ____ % Infected ____ Case % Infected ____ % Infected ____ 
Total All Close Contacts…. _____ 
Number Tested…. _____ 
Total All Casual Contacts…. _____ 
Number Tested…. _____ 
Number Not Infected…. _____ Number Not Infected…. _____ 
Number Infected…. _____ Number Infected…. _____ 
Percent Infected…. _____% Percent Infected…. _____% 
Number Converters (last 2 years)…. _____ Number Converters (last 2 years)…. _____ 
Number with Disease…. _____ Number with Disease…. _____ 
Close contacts are not just household contacts; they can also be work, school, and leisure contacts. 
Conversely, not all household contacts are necessarily close contacts. Figure adapted from the 
Mississippi State Dept. of Health’s form. 
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VI. GLOSSARY OF TERMS7 
Adherence: The willingness and/or ability of patients to maintain responsibility for 
following the treatment plan by taking anti-tuberculous medications as prescribed 
and by keeping necessary health care appointments. 
Case Investigation/Case Assessment: The investigation conducted by the local 
Health Department/Board of Health designated nurse to determine the potential the 
patient has to transmit disease to others, the risk of infection for contacts based on 
level and duration of exposure, and the medical, environmental, economic and 
social factors which may influence adherence to the prescribed treatment plan. 
Clinically Suspected Case of Tuberculosis (“Suspect”): A condition in which the 
individual has acid fast bacilli (AFB) in the sputum or other body fluid or tissue as 
evidenced by a laboratory smear; or has chest x-ray or other diagnostic findings 
interpreted as probable tuberculosis by a qualified medical authority. 
Confirmed Case of Tuberculosis (“Case”): Refers to meeting the criteria as set forth 
by the federal Centers for Disease Control and Prevention (CDC) to verify a case as 
tuberculosis disease (See Reporting Section of Clinic Manual for Case Definition). 
Contact: An individual that has shared the same indoor airspace with a person with 
communicable tuberculosis disease for a sufficient amount of time so that there is 
a probability that transmission of tuberculosis has occurred. 
Contact Investigation: The procedure of tracing, testing and evaluating persons 
who have been in contact with a person with potentially infectious tuberculosis. 
Course of Therapy: A complete course of therapy is defined as ingesting a 
minimum of 80% or more of the recommended amount of doses (for self-
administered therapy, complete therapy can be assumed if the patient picked up 
100% of the prescribed refills and there were no indications of nonadherence 
observed). 
Direct Case Manager: a registered nurse, designated by the local board of health, 
who has the overall responsibility for initiating, coordinating, implementing, and 
evaluating the patient’s treatment plan until the completion of therapy. The nurse 
case manager also assists the patient in accessing other community resources, 
such as social services, that will assist him or her with adherence to therapy. 
7Commonwealth of Massachusetts Regulations, Standards for Management of Tuberculosis Outside 
Hospitals, CMR 365:004 Definitions. 
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Directly Observed Therapy (DOT): The direct observation, by a health care provider 
or other designated responsible person, of the ingestion of prescribed anti-
tuberculous medication by the patient. Observation by a family member is not 
considered DOT. 
Enablers: A term used to describe anything that assists (enables) the patient to 
more readily complete therapy or access the treatment delivery system. Enablers 
include providing transportation, bus fares, flexible clinic hours, etc. 
Incentives: Something that motivates a patient to take his or her medication, keep 
clinic appointments or assist him or her to complete therapy. Incentives include 
food coupons, food or coffee at the clinic, cash or any individualized gift or reward 
for adhering to the treatment plan. 
Outreach Educator (ORE): An individual who has been specifically trained by the 
Division of Tuberculosis Prevention and Control and/or the Refugee and Immigrant 
Health Program (RIHP) to assist with TB case management services to priority 
patients. The outreach educator also provides social support and advocacy for 
individuals in a culturally competent manner. 
Self-Administered Therapy: Self-administered therapy is the ingestion of prescribed 
anti-tuberculous medication by the patient. 
Source Case Investigation: The procedure of tracing, testing and evaluating 
contacts to identify the source of tuberculosis disease transmission to the 
presenting case or an infected individual. This is particularly important for children 
under five years of age. 
Tuberculosis Surveillance Area (TSA) Nurse: A Public Health Nursing Advisor who 
works for the Division of Tuberculosis Prevention and Control and is responsible for 
coordinating tuberculosis activities in a designated geographic region of the state. 
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VII. COMMONWEALTH OF MASSACHUSETTS REGULATIONS 
105 CMR 350.000: Determining Active Tuberculosis 
Section 
350.001: Purpose 
350.002: Authority 
350.003: Citation 
350.100: Determination 
350.001: Purpose 
105 CMR 350.000 establishes procedures for determining the 
existence of active tuberculosis. 
350.002: Authority 
105 CMR 350.000 is adopted under the authority of M.G.L. c. 
111, §§ 3 and 94A through 94H. 
350.003: Citation 
105 CMR 350.000 shall be known, and may be cited as 105 CMR 
350.000: Determining Active Tuberculosis. 
350.100: Determination 
A) Sufficient evidence of active communicable tuberculosis shall be 
based upon one of the two indicators below: 
1) A laboratory report of sputum or other bodily fluid or tissue 
found to contain tubercle bacilli, as evidenced by culture or other 
definitive diagnostic test, or suspected to contain tubercle bacilli as 
evidenced by smear. 
2) Chest x-ray findings interpreted as active tuberculosis by a 
qualified physician may be used as evidence for active tuberculosis 
when it is not possible to have a laboratory report showing a positive 
smear and/or positive culture or other definitive diagnostic test for 
the tubercle bacilli. 
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B) When tubercle bacilli have thus been found or suspected, the 
individual shall be considered to have active communicable 
tuberculosis until the following criteria are met: 
1) The individual receives an adequate and complete course of 
tuberculosis drug therapy as defined by the American Thoracic 
Society guidelines and three successive cultures of specimens 
collected at intervals of one week, or other definitive diagnostic test, 
shall demonstrate no tubercle bacilli, or 
2) Until clinical or laboratory evidence leads to a diagnosis other 
than tuberculosis. 
Regulatory Authority 
105 CMR 350.000: M.G.L. c. 111, §§ 3 and 94A through 94H. 
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105 CMR 360.000: Tuberculosis Treatment Unit 
Standards for Admission, Treatment and Discharge 
Section 
360.001: Purpose 

360.002: Authority 

360.003: Citation 

360.004: Definitions 

360.100: Designation 

360.200: Admissions 

360.300: Treatment Standards 

360.400: Discharge 

360.001: Purpose 
105 CMR 360.000 sets forth the standards of admission, 
treatment, and discharge of tuberculosis patients to and from the 
State Designated Tuberculosis Treatment Unit. 
360.002: Authority 
105 CMR 360.000 is adopted under the authority of M.G.L. c. 
111, §§ 3, 5, 6, 77, 79 and 94D. 
360.003: Citation 
105 CMR 360.000 shall be known, and be cited as the Standards 
of Admission, Treatment and Discharge of Tuberculosis Patients in the 
State Designated Tuberculosis Treatment Unit, 105 CMR 360.000. 
360.004: Definitions 
Acid Fast Bacilli: Organisms that retain certain stains even after being 
washed with acid alcohol. Most are mycobacteria. When seen as 
stained smear of sputum or other clinical specimen, a diagnosis of 
tuberculosis should be considered. 
Adherence: The willingness and/or ability of patients to maintain their 
share of the responsibility for their therapy by taking their anti-
tuberculosis medications as prescribed and by keeping the necessary 
health care appointments. 
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Clinically Suspected Tuberculosis: A condition in which the individual 
has acid-fast bacilli in the sputum or other bodily fluid or tissue as 
evidenced by a laboratory smear; or has chest x-ray findings 
interpreted as probable tuberculosis by a qualified medical authority. 
Communicable: The ability to transmit disease from one person or 
animal to another. 
Confirmed Case of Tuberculosis: “Confirmed Case” refers to meeting 
the criteria as set forth by the federal Centers for Disease Control and 
Prevention (CDC) to verify a case as tuberculosis disease. 
Division of Tuberculosis Control or Division: The program within the 
Department of Public Health, which administers the provisions of 105 
CMR 360.000. 
Drug Resistant Tuberculosis: Tuberculosis caused by tubercle bacilli 
that are unresponsive to one or more anti-tuberculosis drugs. 
Tubercle Bacillus/Bacilli: A bacillus (bacteria) causing tuberculosis; 
usually refers to Mycobacterium tuberculosis. 
360.100: Designation 
The Division of Tuberculosis Control has the responsibility for 
designating/contracting with a treatment facility for a specialized 
Tuberculosis Treatment Unit and shall be responsible for the 
supervision and control of admissions, treatment and discharges. 
Authority for the management of persons with tuberculosis or 
clinically suspected tuberculosis, admissions and discharges may be 
delegated to the treatment facility through contractual agreement 
and/or written policy. 
360.200: Admissions 
A) Admission to the Tuberculosis Treatment Unit (TTU) is reserved 
for persons with a confirmed case of tuberculosis or clinically 
suspected tuberculosis who cannot or should not be managed in the 
outpatient setting. The primary admission reasons are as follows: 
1) Continued inability or unwillingness to abide by proper medical 
treatment for confirmed or clinically suspected tuberculosis in a 
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communicable form. The admission may be voluntary or involuntary. 
If the admission is involuntary, the procedures set forth in M.G.L. c. 
111, §§ 94A through 94C shall be followed. Least restrictive 
measures shall be used first, and the patient shall be given the 
opportunity for voluntary admission prior to an involuntary 
admission. 
2) Complex medical management problems that require the close 
supervision of an inpatient setting. These include, but are not limited 
to: Persons with drug resistant disease or persons with progressive 
tuberculosis disease that are not improving with outpatient 
management; persons with toxic reactions to therapy; and persons 
with concurrent illnesses which interfere with or prohibit successful 
outpatient treatment of tuberculosis. 
3) Persons with a confirmed case of tuberculosis or clinically 
suspected tuberculosis, in a communicable form, who have living 
arrangements in congregate settings where respiratory isolation is 
not possible and the public health is endangered. 
B) Boards of health, hospitals or other health care providers who 
initiate the admission process shall review the appropriateness and the 
procedure for the admission with the medical director of the TTU or 
with his/her designee. 
C) The TTU shall send the Division of Tuberculosis Control written 
notification of all accepted admissions within five days of admission. 
The Division of Tuberculosis Control shall also receive from the 
designated TTU written notification of all requests for admission that 
were denied within five days of this denial. The information required in 
such notifications shall be determined by the Division of Tuberculosis 
Control. 
D) The TTU is responsible for billing third-party payors and for 
seeking insurance benefits for those who are eligible for such benefits. 
The Commonwealth is the payor of last resort; however, no patient 
shall be denied care and treatment for tuberculosis because of inability 
to pay. 
360.300: Treatment Standards 
A) Medical treatment for tuberculosis shall be according to the 
current standards set forth by the federal Centers for Disease Control 
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and Prevention (CDC) and the American Thoracic Society (ATS) or 

other qualified medical authority. 

B) Appropriate services for concurrent medical and psychosocial 

problems which affect adherence to proper medical care for 

tuberculosis shall be part of the patient treatment plan.

360.400: Discharge 
A) Discharge planning shall involve the TTU staff and other health 
care providers within the treatment facility, the Division of 
Tuberculosis Control, the local board of health from the community 
where the patient did or will reside, and other appropriate community 
agencies. The designated discharge planner for the TTU shall be 
responsible for consulting with the necessary personnel from the 
treatment facility, the Division of Tuberculosis Control, and 
appropriate community agencies and shall arrange for discharge 
planning meetings. The Division of Tuberculosis Control shall ensure 
that the appropriate local board of health personnel are involved in the 
discharge plan. 
B) Multi-disciplinary health care provider conferences shall be held at 
least monthly to review patient progress and discharge plans. 
C) The TTU shall notify the Division of Tuberculosis Control three 
days prior to the discharge of the patient. The TTU shall also report 
this discharge, in writing, within five days after the discharge. 
D) Within two weeks after the discharge, the appropriate staff of the 
TTU shall prepare and send admission, treatment and discharge data 
(as determined by the Division of Tuberculosis Control) to the Division 
of Tuberculosis Control and the local health departments for the 
purposes of data analysis and program planning. 
Regulatory Authority 
105 CMR 360.000: M.G.L. c. 111, §§ 3, 5, 6, 77, 79 and 94D. 
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105 CMR 365.000: Standards for Management of Tuberculosis Outside Hospitals 
Section 
365.001: Purpose 

365.002: Authority 

365.003: Citation 

365.004: Definitions 

365.100: Public Health Precautions 

365.200: Case Management 

365.300: Medical Care and Follow Up 

365.400: Tuberculosis Infection Management 

365.500: Notification 

365.600: Discharge of Tuberculosis Patient into Outpatient Treatment 

365.001: Purpose 
The purpose of 105 CMR 365.000 is to protect the public health 
through standards for outpatient management of tuberculosis. The 
objectives are to enhance treatment adherence, to provide clinical 
monitoring, to insure completion of therapy through public health case 
management and to describe the responsibilities and requirements for 
case reporting. 
365.002: Authority 
105 CMR 365.000 is adopted under the authority of M.G.L. c. 111, 
§§ 3, 5, 6, 7, 18, 81, 94H, 95 and c. 111D, § 6. 
365.003: Citation 
105 CMR 365.000 shall be known, and may be cited, as 105 CMR 
365.000: Standards for the Management of Tuberculosis (TB) Outside 
Hospitals. 
365.004: Definitions 
Acid Fast Bacilli: Organisms that retain certain stains even after 
being washed with acid alcohol. Most are mycobacteria. When seen 
as stained smear of sputum or other clinical specimen, a diagnosis of 
tuberculosis should be considered. 
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Adherence: The willingness and/or ability of patients to maintain their 
share of the responsibility for their therapy by taking their anti-
tuberculosis medications as prescribed and by keeping the necessary 
health care appointments. 
Case Assessment: The investigation conducted by the local board of 
health nurse to determine the potential the patient has to transmit 
disease to others, the risk of infection for contacts based on level and 
duration of exposure, and the medical, environmental, economic and 
social factors which may influence adherence to the prescribed 
treatment plan. 
Clinically Suspected Tuberculosis: A condition in which the individual 
has acid-fast bacilli in the sputum or other bodily fluid or tissue as 
evidenced by a laboratory smear; or has chest x-ray findings 
interpreted as probable tuberculosis by a qualified medical authority. 
Communicable: The ability to transmit disease from one person or 
animal to another. 
Confirmed Case of Tuberculosis: “Confirmed Case” refers to an 
individual who meets the federal Centers for Disease Control and 
Prevention (CDC) requirements to verify a case of tuberculosis 
disease. 
Contact: An individual that has shared the same airspace with a 
person with communicable tuberculosis for a sufficient amount of time 
so that there is a probability that transmission of tuberculosis has 
occurred. 
Contact Investigation: The procedure of tracing, testing and evaluating 
persons who have been in contact with a patient with potentially 
infectious tuberculosis. 
Division of Tuberculosis Control or Division: The program within the 
Department of Public Health, which administers the provisions of 105 
CMR 365.000. 
Droplet Nuclei: The microscopic airborne particles of aerosolized 
sputum, which can carry tubercle bacilli to the lungs of susceptible 
individuals. 
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Drug Resistant Tuberculosis: Tuberculosis caused by tubercle bacilli 
that are unresponsive to one or more anti-tuberculosis drugs. 
Enablers: A term used to describe anything that helps the patient to 
more readily access the treatment delivery system. These include: 
providing transportation, bus fares, helping to obtain a driving license, 
etc. 
Incentives: “Motivators”: or something which motivates a patient to 
take his or her medication, keep clinic appointments or do anything 
else that is necessary to ensure completion of therapy. Incentives 
include food coupons, cash or any individualized gift or reward for 
adhering to the treatment plan. 
Nurse Case Manager: A registered nurse, designated by the local 
board of health, who has the overall responsibility of monitoring and 
coordinating the implementation of the patient’s treatment plan until 
the completion of therapy. The nurse case manager also assists the 
patient in obtaining other community resources, such as social 
services, that will assist him or her with adherence to therapy. 
Tubercle Bacillus/Bacilli: A bacillus (bacteria) causing tuberculosis; 
usually refers to Mycobacterium tuberculosis. 
Tuberculosis Infection: Condition in which living tubercle bacilli are 
present in an individual, without producing clinically active disease. 
The infected individuals usually have a positive tuberculin skin test but 
are not infectious. 
Tuberculosis Surveillance Area (TSA) Nurse: A Public Health Nursing 
Advisor who works for the Division of Tuberculosis Control and is 
responsible for all tuberculosis activities in a designated regional 
geographic area of the state. 
365.100: Public Health Precautions 
A) The period of infectivity for tuberculosis is defined in 105 CMR 
300.200: Isolation and Quarantine Regulations. 105 CMR 300.200 
determines when health care providers may discontinue isolation 
precautions and when individuals with confirmed or clinically 
suspected tuberculosis may resume community activities and 
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community living. This includes, but is not limited to, resuming 
employment, school attendance, shelter living or other residential 
living arrangements. 
B) Outpatient facilities (including but not limited to, hospital 
outpatient departments, clinics and medical office buildings where 
active tuberculosis cases are seen for treatment) shall follow current 
national and local infection control guidelines for the isolation of 
individuals who are excreting tubercle bacilli into the room air and who 
may be infectious to others. 
365.200: Case Management 
A) Case management for tuberculosis is defined as the coordination 
of the necessary medical, nursing, outreach and social service systems 
which ensure that all persons with confirmed and clinically suspected 
tuberculosis are started on appropriate therapy, and that all persons 
with confirmed tuberculosis complete an appropriate and effective 
course of treatment. 
B) The Division of Tuberculosis Control shall assign regional 
Tuberculosis Surveillance Area (TSA) Nurses, as necessary, to work 
cooperatively and in consultation with local board of health authorities 
and the nurse case manager, designated by the local board of health, 
to ensure that a case management system is in place for every 
confirmed or clinically suspected case of tuberculosis. 
C) The following measures are a requirement of the case 
management system: 
1) The case shall be reported to the Massachusetts Department of 
Public Health, Division of Tuberculosis Control, as required by 105 
CMR 365.500. 
2) All persons with confirmed or clinically suspected tuberculosis 
shall have a nurse case manager designated by the local board of 
health who will work in consultation and cooperation with the 
regional TSA nurse, as necessary, to manage persons with 
confirmed or clinically suspected tuberculosis. This case 
management is required regardless of the source of health care 
(public or private) and the ability to pay for the services or 
medications. 
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3) In consultation with the treating health care provider, the nurse 
case manager, designated by the local board of health, determines 
that a medical treatment plan is in place and is in accordance with 
the American Thoracic Society (ATS) and federal Centers for Disease 
Control and Prevention (CDC) standards for care. 
4) The initial case assessment and contact investigation by the 
local board of health shall begin within three working days of 
notification of a potential case of tuberculosis. Contacts to the case 
shall be identified and categorized for their risk of tuberculosis 
infection as determined by their level of exposure and the person’s 
potential for generating air-borne tubercle bacilli (droplet nuclei). 
Contacts shall be investigated according to the ATS/CDC standards 
and the policies of the MDPH, Division of Tuberculosis Control. 
Contact investigation reports shall be prepared and given to the TSA 
nurse for the region, according to the policies developed by the 
Division of Tuberculosis Control. 
5) Starting with the first visit to a potential case by the nurse 
designated by the local board of health, there shall also be an 
assessment of whether there are factors that affect adherence with 
therapy. This includes, but is not limited to: poor access to health 
care facilities; homelessness; work schedules; poverty; language 
barriers; cultural beliefs; substance abuse; mental health status; 
recent immigration; and medical conditions which may interfere with 
treatment. (Complete guidelines are available from the Division of 
Tuberculosis Control). 
6) An individualized nursing care plan shall be developed by the 
local board of health’s designated nurse case manager and, 
depending upon the identified risk factors for non-adherence to 
therapy, the plan shall include the following: 
a) A plan to remove barriers to adherence through: 
enablers which increase access to care; incentives 
which motivate persons to remain on appropriate 
therapy; and referrals to community agencies and 
providers which can assist with identified 
psychosocial or medical problems. 
b) Educational services to the individual who has 
confirmed or clinically suspected TB. The topics 
include, but are not limited to, the following: 
1. how TB is spread 
2. how to prevent the spread of TB 
3. how to take medications 
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4. the effects of TB if not adequately treated 
5. the importance of completing the prescribed course of 
treatment 
6. the patient’s responsibility in curing his or her own disease 
7. the consequences to the individual if he or she is unwilling to 
adhere to the treatment plan 
8. causes of drug resistant TB and its effects 
c) The number of nursing and outreach worker visits and the 
level of social support shall depend upon the assessed level of 
adherence to therapy and medical status. 
d) Directly Observed Therapy (DOT) by medical/ nursing/ 
outreach caregivers or other individuals identified by the local board 
of health shall be employed when there is an identified risk to 
continued adherence to therapy. 
e) Voluntary hospitalization/ institutionalization in the case of 
person with complex medical, psycho-social, and infection control 
management problems. 
f) Involuntary hospitalization or confinement may be necessary 
when there is documented non-adherence to the appropriate 
medical follow-up and treatment for tuberculosis, and the public 
health is threatened as a result of this non-adherence. Least 
restrictive measures shall be employed before more restrictive 
measures are imposed. (See M.G.L. c. 111, § 94A for involuntary 
commitment procedures) 
365.300: Medical Care and Follow-Up 
A) All persons with confirmed or clinically suspected tuberculosis 
shall have an identified medical doctor, qualified and licensed to 
practice medicine, or a nurse practitioner licensed to practice in the 
expanded role under the supervision of a qualified medical doctor, to 
provide medical supervision. 
Medical treatment for tuberculosis shall be according to the current 
standards set forth by the federal Centers for Disease Control and 
Prevention (CDC) and the American Thoracic Society (ATS), or other 
qualified medical authority, for chemotherapy and follow-up. The 
Division of Tuberculosis Control shall make these standards available 
and provide consultation regarding appropriate therapy when 
necessary. 
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B) Providers responsible for medical management of persons with 
confirmed or clinically suspected tuberculosis disease shall work in 
cooperation with the local board of health and the Division of 
Tuberculosis Control for the purposes of case management as outlined 
in 105 CMR 365.200. 
C) Providers must also notify the local board of health in the town 
where the patient resides and the Division of Tuberculosis Control, of 
any person with confirmed or clinically suspected tuberculosis in a 
communicable form, who is unable or unwilling to receive proper 
medical care and, as such, poses a threat to the public health. 
365.400: Tuberculosis Infection Management 
Management and treatment of persons infected with tuberculosis, 
but without active disease, shall be provided in accordance with the 
current standards set forth by the CDC/ATS or other qualified medical 
authority. 
365.500: Notification 
Any health care provider, laboratory, board of health, office of 
administration of a city, state or private institution or hospital who has 
knowledge of a case of confirmed tuberculosis or clinically suspected 
tuberculosis, as defined in 105 CMR 365.004, shall notify the Division 
of Tuberculosis Control within 24 hours. Upon receipt of such notice, 
the Division of Tuberculosis Control shall notify the local board of 
health within 24 hours. Cases involving residents of the City of Boston 
having confirmed or clinically suspected tuberculosis shall be reported 
to both the Department and to the Boston Department of Health and 
Hospitals within 24 hours. This notice shall include the case name, 
date of birth, age, sex and address. 
365.600: Discharge of Tuberculosis Patient Into Outpatient Treatment 
Any acute or chronic care hospital or any other institution which 
provides health care to residents, including but not limited to: prisons; 
jails; residential treatment centers; nursing homes and rest homes, 
which plan to discharge a person with confirmed or clinically 
suspected tuberculosis into the community for outpatient tuberculosis 
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treatment, shall do discharge planning in collaboration with the State 
Division of Tuberculosis Control. 
The Division shall be notified of such persons with confirmed or 
clinically suspected tuberculosis, upon his or her admission to the 
hospital or institution, in order to begin the process for the 
development of the outpatient case management plan. 
The Division of Tuberculosis Control shall notify and work with the 
local board of health nurse responsible for case management. 
A pre-discharge conference regarding case management shall be 
held and shall include the designated board of health case manager, 
the TSA nurse from the Division of Tuberculosis Control, as 
necessary, as well as the discharge planner and medical providers. A 
plan for appropriate medical, nursing and community agency follow-up 
shall be made prior to discharge into the community. 
Regulatory Authority 
105 CMR 365.000: M.G.L. c. 111, §§ 3, 5, 6, 7, 18, 81, 94H, 95; 
c. 111D, § 6. 
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DEPARTMENT OF PUBLIC HEALTH 
DIVISION OF TUBERCULOSIS CONTROL 
PROCEDURE FOR COMPULSORY HOSPITALIZATION 
Compulsory hospitalizations include a short-term 15-day observation period and a 
long-term court commitment under the authority of Massachusetts General Laws 
(MGL), chapter 111, section 94-A, 94-B and 94-C. Regulations supporting the law 
are 105 CMR 350.000, 360.000 and 365.000. 
The designated inpatient Tuberculosis (TB) Treatment Center is located at Lemuel 
Shattuck Hospital, in a single treatment unit called the Tuberculosis Treatment Unit 
(TTU). 
94 - A: Local Certification Requesting Hospitalization of Tuberculosis Patient 
for Fifteen Days Observation in the Tuberculosis Treatment Center. 
Local Board of Health Responsibilities: 
1. "Local Certification" form filled out by appropriate petitioner as allowed by law 
(board of health, health director, member of board of health or two physicians). 
2. The regional Tuberculosis Surveillance Area (TSA) nurse from the Division of 
Tuberculosis Control advises the petitioner(s) regarding the required documentation. 
For the City of Boston, where a TSA nurse is not assigned, this advice is given by 
the Director of Prevention, Policy and Clinical Services, or designated professional 
staff. 
3. There must be laboratory evidence (positive AFB smear /positive TB Culture) 
and/or chest x-ray findings consistent with active tuberculosis in a communicable 
form. For clarity, the laboratory evidence should contain the first and last positive 
smear/culture reports as well as the first and last negative smear/culture reports. 
Included in the chest x-ray reports should be those with the worst findings as well 
as those that are stable or improving. 
4. There must be clear evidence that the patient is unable or unwilling to accept 
proper medical treatment. This should include dates of outpatient treatment 
attempts and dates when the patient failed to keep scheduled appointments. Least 
restrictive measures, such as incentives and enablers, which help patients adhere 
to treatment, outreach worker involvement, and directly observed therapy (DOT) 
are examples of outpatient treatment attempts. Regulation 105 CMR 365.200 
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describes in further detail the case management system that ensures least 
restrictive measures. 
5. The "Local Certification" form is notarized and sent with the attached 
documentation reports to the Division of TB Control. 
6. In an emergency situation when the “Local Certification” information needs to 
be processed as soon as possible by the Division of TB Control, permission may be 
granted to send the notarized form first by fax and then by delivery. In these 
instances, it is necessary to review the request with the Director of Prevention, 
Policy and Clinical Services (or designee). 
State TB Control Responsibilities: 
1. The "Local Certification" form is reviewed by the Director of Prevention, Policy 
and Clinical Services, or designee, for appropriate documentation. This information 
is summarized in the State 94-A form called "Order for Admission for Fifteen Days' 
Observation to State Tuberculosis Treatment Center". 
2. The Administrative Assistant, or designee, for the Division of TB Control types 
the following: 
a). The summary, prepared by the Director of Prevention, Policy and Clinical 
Services (or designee), from the "Local Certification" onto the three State 94-A 
(yellow) forms. 
b). The form authorizing the local police department to transport the patient to 
the State TB Treatment Center (Lemuel Shattuck Hospital). 
3. All three of the completed 94-A forms, and the police form must be signed by 
the Commissioner of the Department of Public Health or his/her designee (usually 
the Assistant Commissioner / physician in the Bureau of Communicable Disease). A 
Notary Public must witness the signing and notarize the 94-A forms. The Director 
of Prevention, Policy and Clinical Services, or designated professional staff, will be 
available for questions and review of the completed forms. 
4. The Administrative Assistant, or designee, makes 2 copies of the original "Local 
Certification" papers, the attached documentation reports and the police form. The 
following folders are then prepared: 
a). Folder labeled with the name of the original petitioners (e.g. Health 
Department) containing one signed original 94-A form, an attached copy of the 
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"Local Certification" with the documentation reports, and a copy of the police 

authorization form. 

b). Folder labeled Lemuel Shattuck Hospital containing one signed original 94-A 

form, an attached copy of the "Local Certification" with the documentation 

reports, and the original police authorization form. 

c). Folders (a) and (b) (above) are either picked up by or sent to the local 
petitioner, depending upon how quickly the signed forms are required by the 
petitioner, in order to proceed with the hospitalization. The petitioner keeps a 
folder for the local records and the other folder labeled “Lemuel Shattuck 
Hospital” is sent with the patient to this hospital. The police authorization form, 
contained in this folder, is presented to the police escort. 
d). A red colored folder, labeled with the patient's name, remains with the 
Division of Tuberculosis Control and contains the original "Local Certification", 
with the documentation reports, attached to a signed original 94-A form and a 
copy of the police authorization form. 
e). For admissions from areas outside of Boston a copy of the “Local 
Certification” form is sent to the regional TSA nurse. 
5. The Director of Prevention, Policy and Clinical Services, or designee, reviews 
the procedure for admission to Lemuel Shattuck Hospital TTU with the local 
petitioner. The petitioner is advised to contact the Medical Director of the TTU and 
review patient information prior to admission. 
94 - B: Hospital Application for Transfer of Tuberculosis Patient to the State 
Tuberculosis Treatment Center for Fifteen Days' Observation. 
1. Hospitalized patients, with evidence of active tuberculosis in a communicable 
form, who indicate their desire to leave the hospital against medical advice, may 
(pending approval) be transferred directly to the Tuberculosis Treatment Unit (TTU) 
at Lemuel Shattuck Hospital for a 15 day observation period. 
2. Calls from hospitals to the Division of Tuberculosis Control regarding a potential 
94-B admission are directed to the Director of Prevention, Policy and Clinical 
Services, or designee. The caller is advised of the following: 
a). There must be laboratory evidence (positive AFB smear/positive TB culture) 
and/or chest x-ray findings consistent with active tuberculosis in a 
communicable form. 
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b). The Medical Director, or designee, of the TTU has the authority to approve 
admissions for the TTU. 
c). Once the decision is made to detain the patient for a 15 day observation 
period, the hospital administrator must transfer the patient to Lemuel Shattuck 
Hospital or detain the patient at his/her own institution. If the patient does not 
go to Lemuel Shattuck Hospital, the administrator of the hospital, where the 
patient is detained, must immediately petition the courts for a prolonged 
hospital stay under the authority of Massachusetts General Laws Chapter 94-C. 
d). Forms for documenting the need for a 94-B admission are available through 
the Division of TB Control and may be faxed to the referring hospital. 
3. Weekend and off-hour calls are referred to the Medical Director (or designee) of 
the TTU at Lemuel Shattuck Hospital for approval and admission. 
4. Patients admitted to Lemuel Shattuck Hospital on a voluntary basis are also 
subject to the rules of MGL, Chapter 111, Section 94-B, if he/she indicates a desire 
to leave against medical advise and would subsequently become a threat to the 
public health. In these instances, the medical director (or designee) of the TTU 
needs to contact the Office of the General Counsel and ask the attorney assigned 
to Lemuel Shattuck Hospital to petition the court as required under MGL Chapter 
111, Section 94-C. (See below). The patient is then detained until the court 
hearing. 
94 - C: Court Orders for Long-Term Hospitalization of Uncooperative 
Tuberculosis Patient to the State Tuberculosis Treatment Center 
1. Under the following conditions long-term court orders may be necessary for 
patients who are currently being detained for a 15-observation period under the 
authority of 94-A or 94-B: 
a). The patient continues to be unable or willing to accept proper medical care 
and this can be clearly documented in the patient record or through the 
testimony of health care workers who have made treatment attempts. 
b). The court must be petitioned by the end of the 15 day observation period at 
Lemuel Shattuck Hospital TTU, or immediately in the case where another 
hospital chooses to detain a patient under the authority of 94-B. 
4 

2. Two physicians must examine the patient and report the evidence that he/she is 
unwilling or unable to accept proper care and thereby poses a serious danger to the 
public health. 
3. The DPH Counsel for Lemuel Shattuck Hospital may ask for the testimony of 
other health care workers who have documentation and/or knowledge of the 
patient's inability or unwillingness to accept proper care. 
4. Due process for the patient includes a right to counsel. 
5. The judge may assign a specific time frame for commitment (usually until 
treatment is finished); however, the patient has the right to another hearing 6 
months from the original hearing  (section 94-G). 
6. The patient may be discharged from the hospital prior to the completion of 
treatment if Lemuel Shattuck Hospital, in collaboration with the Division of TB 
Control and the local board of health, determines that it is in the best interest of 
the patient and the public health (section 94-F). 
Telephone for Division of TB Control: 
(617) 983-6970 
(617) 983-6990 - FAX 
Telephone for Lemuel Shattuck Hospital TTU: 
(617) 971-3352 
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LOCAL CERTIFICATION 
(For Hospitalization as Uncooperative Tuberculosis Patient) 
We ................................................................................................................................... 
.................................................................................................................................................

. 

(Board of Health - Health Director - Member of Board of Health - or two physicians duly licensed to

practice medicine in the Commonwealth) as subscribers, being severally and duly sworn, do make

oath and depose as follows: 

We find that ........................................................................Date of Birth....................................

residing at 
.................................................................................................................................. 
(street and no.) (city or town) 
County of ...........................................Commonwealth of Massachusetts is:

(1) afflicted with active tuberculosis, and

(2) is unwilling or unable to accept proper medical treatment, and 

(3) is thereby a serious danger to the public health

H___therefore should be committed to the State Sanatorium Treatment Center as required by Sections

94A and 

94C of Chapter 111 of the General Laws. We hereby refer h___to the Commissioner of Public Health

for further examination in accord with the above law.

The above findings of the subscribers are based on the following facts:

(1) Evidence of active tuberculosis in a communicable form:

(a) Laboratory findings:  (specify and attach report) 
(b) Chest X-ray findings: (specify and attach report) 
(c) Other facts: 
(2) Outpatient treatment efforts made prior to plans for involuntary confinement: (Specify treatment 
attempts and enablers such as outreach worker assignments, directly observed therapy, social and 
psychiatric support systems, and incentives to receive appropriate care.) 
(over) 
1

(3) Inability or unwillingness to abide by proper medical treatment for tuberculosis in a communicable 
form and thereby a serious threat to the public health: (Include dates of appointments not kept as well 
as supporting evidence that the individual will not accept appropriate care.) 
OTHER 
Brief description of pertinent medical and psycho-social problems:  (Include date of tuberculosis 
diagnosis and probable duration, other relevant medical conditions, current living arrangements, 
household members, a list of children and their ages, and patient's occupation. 
.............................................................................. 
(Petitioner) 
Subscribed and sworn to before me on this .................day of ...................................20 ............... 
............................................................................. 
(Notary or Justice of the Peace) 
Forms supplied by: Mass. Dept. of Public Health, Bureau of Communicable Disease Control 
Division of Tuberculosis Control 
305 South Street 
Jamaica Plain, MA 02130 
2

EPIDEMIOLOGIC REPORT ON A TUBERCULOSIS CASE 
Case name: _____________________________________ 
Last First 
Specimen Source: _______________________________ 
Case Smear Status: ____________  Culture: ___________ 
Case CXR Results: ____________________________ 
Person Completing Form: __________________________ 
Telephone #:  (  )___________________ 
Date Worksheet Started:  _____/______/_____ 
_
Return this form to: 
Date received in TSA office: 
Exposure Setting Codes: 
[01] – Household [09] – Other - specify 
[02] – Non-household/Friends/Relatives [10] – Unknown 
[03] – Restaurant/Bar [11] - Other Worksite 
[04] – Correctional Facility 
[05] – School/Day Care 
[06] – Nursing Home 
[07] – Shelter 
[08] – Hospital/Acute Care 
Contact #1 ___________________________________________________ DOB: ____/____/____ Mantoux Tests CXR Treatment 
Last First Date Date Normal Abnormal START____/____/____ 
______________________________________________________________ AGE: ____ ____ Administer END ____/____/____ 
Address City Exposure Setting Code: ____ ____ Results  R Noncav INH_________________ 
 R Male  RFemale Country of Birth: ________________________ in mm  R Cav RIF/PZA _____________ 
Relationship: Contact is the ________________________ of the case. Comments: Other _______________ 
Contact #2 ___________________________________________________ DOB: ____/____/____ Mantoux Tests CXR Treatment 
Last First Date Date Normal Abnormal START____/____/____ 
______________________________________________________________ AGE: ____ ____ Administer END ____/____/____ 
Address City Exposure Setting Code: ____ ____ Results  R Noncav INH_________________ 
 R Male  RFemale Country of Birth: ________________________ in mm  R Cav RIF/PZA _____________ 
Relationship: Contact is the ________________________ of the case. Comments: Other _______________ 
Contact #3 ___________________________________________________ DOB: ____/____/____ Mantoux Tests CXR Treatment 
Last First Date Date Normal Abnormal START____/____/____ 
______________________________________________________________ AGE: ____ ____ Administer END ____/____/____ 
Address City Exposure Setting Code: ____ ____ Results  R Noncav INH_________________ 
 R Male  RFemale Country of Birth: ________________________ in mm  R Cav RIF/PZA _____________ 
Relationship: Contact is the ________________________ of the case. Comments: Other _______________ 
Contact #4 ___________________________________________________ DOB: ____/____/____ Mantoux Tests CXR Treatment 
Last First Date Date Normal Abnormal START____/____/____ 
______________________________________________________________ AGE: ____ ____ Administer END ____/____/____ 
Address City Exposure Setting Code: ____ ____ Results  R Noncav INH_________________ 
 R Male  RFemale Country of Birth: ________________________ in mm  R Cav RIF/PZA ___P_________ 
Relationship: Contact is the ________________________ of the case. Comments: Other _______________ 
Contact #5 ___________________________________________________ DOB: ____/____/____ Mantoux Tests CXR Treatment 
Last First Date Date Normal Abnormal START____/____/____ 
______________________________________________________________ AGE: ____ ____ Administer END ____/____/____ 
Address City Exposure Setting Code: ____ ____ Results  R Noncav INH_________________ 
 R Male  RFemale Country of Birth: ________________________ in mm  R Cav RIF/PZA _____________ 
Relationship: Contact is the ________________________ of the case. Comments: Other _______________ 
For office use only 

TBID Number: __________________________ Date received in SLI office: Reviewed by Epidemiologist

6/2000 FORMMDPH - TB03 Routing: Pink Copy after 1st screening - TSA Nurse White copy after second screening – TSA nurse - MDPH; Blue Copy - Local Health Department 

JANE SWIFT 
GOVERNOR 
ROBERT P. GITTENS 
SECRETARY 
HOWARD K. KOH, MD, MPH 
COMMISSIONER 
The Commonwealth of Massachusetts 
Executive Office of Health and Human Services 
Department of Public Health 
State Laboratory Institute 
305 South Street, Jamaica Plain, MA 02130 
(617) 983-6200 
Bureau of 
Communicable 
Disease Control 
Date: ____________ 
Dear Dr. ________________________: 
The patient(s) listed on the attached sheet have been identified as close contacts to an infectious 
case of Tuberculosis (TB). They plan to contact your office to schedule an evaluation. 
Adults and Children 5 Years of Age and Older: The Division of TB Prevention and Control of 
the Massachusetts Department of Public Health recommends that contacts age 5 and older 
receive a Mantoux PPD skin test and, when indicated, a medical evaluation (including a chest 
radiograph). All persons with a positive skin test (> 5 mm) should be placed on treatment of 
latent TB infection. 
Infants and Children Less Than 5 Years of Age: Young children under 5 years of age should 
immediately receive a medical evaluation. This includes: a Mantoux PPD skin test, a thorough 
physical examination to rule out active pulmonary or extrapulmonary TB, chest radiographs 
(bilateral and anterior-posterior), and prophylaxis with INH, even if the skin test result is 
negative. If the repeat skin test (done 8 to 12 weeks later) is negative, prophylaxis can be 
discontinued.  If positive, then a full course of treatment of latent TB infection (a total of 9 
months of INH) should be prescribed. 
Massachusetts regulations (105 CMR 365.200, section C.4) provide the local health department 
with the legal authority to investigate and report contacts to the Division. The results of the 
testing and medical follow-up of close contacts referred for medical examination are sent to the 
Division and reported in aggregate to the Centers for Disease Control and Prevention. 
Please complete the enclosed form and return by mail or fax to: 
Public Health Nurse’s Name: _______________________________________ 
Local Health Department Address: _______________________________________ 
______________________________________ 
Local Health Department Fax: _______________________________________ 
Yours truly, 
_________________________________, RN 
MDPH TB17 

MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH 
DIVISION OF TUBERCULOSIS PREVENTION AND CONTROL 
TB RECORD # INITIAL CLINICAL EVALUATION FORM 
Hospital I.D.: ______________________ S.S.# (If known): 
NAME, LAST: FIRST: 
D.O.B.:  /  / Sex:  F 
City:  Zip Code: ______________ 
Phone: ( )  R None 
Country of Birth:  R U.S.  R Other: ___________________________________ 
M
Date of Visit: / / 
 R TB Clinic: 
Type of Visit: A1 (MD Visit-with x-ray) 
____ A2 (MD Visit-with no x-ray) 
Date of Visit: / / 
 R Private Provider: 
Address: 
Phone: ( ) 
CLINICAL DATA: Weight: _________ BACTERIOLOGY:  R No Bacteriology Pending 
Previous X-ray Done:  R No  R Yes - Where: _______________________ Source: Date Collected: /  / 
CHEST X-RAY: Date: /  /  R Not Done Smear Result:  R Neg  R Pos  R Pending  R Not Done 
Results:  R Normal  R Cavitary  R Abn/Non-Cavitary  R Unknown Culture Result:  R Neg  R Pos  R Pending  R Not Done 
CXR Status:  R Stable  R Improving Pathology:  R Pathology Done  R No Pathology Done 
 R Worsening  R Unknown Source: Date Collected: / / 
Brief description of findings: Results: ___________________________________________________________ 
_____________________________________________________ 
EVALUATION: 
ATS Classification: 
(0) No TB exposure, not infected ____ (3) Active TB disease, current 
(1) TB exposure, not infected ____ (4) Old TB disease, not current 
(2) TB infection, no disease ____ (5) Suspected disease, diagnosis pending 
Disease Site(s): (Class 3 or 5)  R Pulmonary  R ExtraPulmonary: 
HIV Risk Assessment:  R Not Done  R Done at Clinic  R Done prior to Clinic 
HIV Risk Identified:  R Yes  R No 
 R Referred for Counseling & Testing  R Declined Counseling & Testing 
PRESCRIBED MEDICATIONS: To Start on _____/_____/_____ 
Expected Duration of Therapy: Months 
DRUG DOSAGE FREQ ACTUAL DATE 
STARTED 
Rifater (RFT) 
Rifamate (RFM) 
INH 
RIF 
PZA 
EMB 
__________________________________________________________ 
__________________________________________________________ 
COMPLETE THE FOLLOWING PLAN: 
 R Baseline ALT: ___________  R WNL  R ABNL  R Not Done/Ordered  R Potential for Adherence to Treatment Assessed 
 R eason Treatment of Latent TB Infection not recommended:  R Self-Administered Therapy (No risk factors for non-adherence) 
 R Pregnant - Return after Delivery  R ABN ALT  R Previous Therapy OR 
 R Other: ______________________________________  R Directly Observed Therapy:  R Daily  R Intermittent: X/Week 
 R Patient Declined Treatment of Latent TB Infection Person(s) performing DOT: __________________________________ 
 R Discharged from Clinic/No further Follow-Up Recommended DOT scheduled at:  R Clinic  R BOH  R Home  R Other: 
 R Baseline Eye Check for EMB:  R WNL  R ABNL  R Not Done Patient Education:  (Check all that apply) 
Sputum Ordered:  R Yes  R No  R TB Infection vs. disease explained  R S&S of disease 
Other Tests Ordered:  R Medication risks/benefits explained  R Importance of taking meds 
 R Importance of keeping appointments  R Literature given to patient 
 R Case/Suspect Reported to Division Next Visit: ______/______/______ 
Toll-Free Reporting Number: 1-888-MASSMTB (627-7682)  R Interpreter needed next visit: Language: _________________________ 
COMMENTS: _ 
_ 
Signature:  R M.D. Signature:  R .N. 
8/00 FORM MDPH - TB04B 
MEDICAL RECORD 
Instructions for the Initial Clinical Evaluation Form 
General Instructions: The purpose of this form is to document information on the patient’s initial clinical evaluation visit. This form is 
only completed for the initial visit. Subsequent visits are documented on the Preventive or Case/Suspect Follow Up forms, as appropriate. 
Please print legibly. 
These instructions address areas that may not be self-explanatory or have special instructions. Please fill form out as completely as 
possible. Areas that are required are specifically noted in these instructions. In general, required fields are bolded (excluding the 
section titles). 
TB Record #: Leave blank. The Division completes this upon data entry. 

Identification demographics (left top box): Printing is faint, so addressographs can be used.

All bolded fields in this section are required. Hospital I.D.: Hospital or clinic ID or record number, when applicable. 

Clinic Visits: ‘Date of Visit’, ‘TB Clinic name’, and ‘Type of visit’. Required. 

OR 
Private Provider: Date of Visit and Provider name. Required. 
Clinical Data and Bacteriology: Results and dates required. There are boxes for ‘Not Done’ and ‘Unknown’ results for chest x-rays

and bacteriology. Results of chest X-rays and bacteriology should be ascertained and documented before submitting form. The chest 

diagram is optional for clinic use. For cases and suspects, please attach a copy of radiology, pathology, and bacteriology reports not done 

at the State Laboratory Institute. 

Evaluation: 

ATS Classification: Check appropriate classification. If class 3 or 5 (case or suspect), complete site of disease. 

HIV Risk Assessment: Required. Note: The Division has an HIV risk assessment tool that can be used as a guide for the assessment of 

patients who do not know their HIV status. Document if a risk was identified and any follow-up. 

Medications: Complete when applicable. The ‘Prescribed Medications: To Start on’ date field is necessary for legal purposes to document 

the medication order. For cases and suspects, the standard regimen is four-drug therapy for all patients. Rifater should be used instead 

of INH, RIF, and PZA (for those who are not on directly observed therapy). 

Patient Care Plan: Complete appropriate plan. Note: each patient should be assessed for the potential for adherence to treatment; DOT is 

required for cases and suspects when risk factors for non-adherence are present and is strongly recommended for certain high-risk

preventives.

Reporting: It is the responsibility of the clinic to report every clinically suspected or confirmed case of TB to the Division within 24 

hours. A toll-free number is available (1-888-MASSMTB), or the TB Case/Suspect Reporting Form can be used. 

Comments: Optional for clinic use. 

Signature: Signature(s) are required for legal purposes. 

Distribution:  The Initial Clinical Evaluation form and the TB History form should be distributed together, not separately. Original

copy to Medical Records, a copy to the local health department of the patient’s residence, and a copy the TB Division, Massachusetts 

Dept. of Public Health, State Laboratory Institute, 305 South St., Jamaica Plain, MA 02130. 

NAME, LAST: FIRST: 
D.O.B.:  /  / Sex:  M F 
Street: ______________________________________________ 
City: ________________________________________________ 
Phone: ( )  R None 
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH 
DIVISION OF TUBERCULOSIS PREVENTION AND CONTROL 
TB RECORD # TB HISTORY FORM 
 R Yes: Age at Last Vaccination: 
Date:  / / 
 RTB Clinic: 
TUBERCULIN TESTS:  (Date administered) 
PPD Result mm / / 
Past PPD mm / / 
Past PPD mm / / 
B.C.G.  R No _________ 
Referral Source: ___________________________ Phone: ( ) Civil Surgeon Referral:  R Yes  R No 
Primary Care Provider: _____________________________ Address: ________________________________________ 
DEMOGRAPHIC DATA: EMPLOYMENT DATA: Employed at: __________________________ 
Race:  R White  R Black  R American Indian/Alaskan  R Asian /Pacific Islander Healthcare:  RAcute Care  RLong-term Care 
Ethnicity:  R Hispanic  R Non-Hispanic  RDrug Treatment Center  ROther:_____________ 
Country of Birth:  R U.S.  R Other:  RShelter  RCorrectional Services 
Date of Entry to U.S.: (month/year) /  RStudent  RRetired 
Language spoken at home: ________________________  R Interpreter needed  RUnemployed  ROther employment:____________________ 
MEDICAL HISTORY: Allergies: ____________________  R None Known SYMPTOMS: 
 R Hx Hepatitis: A___ B___ C___  R Pregnant  R Cough: Productive Non-Productive: # of Weeks _____ 
 R Hx TB Disease: Year: _____ Treatment: Months Rx: ______  R Fever  R Hemoptysis  R Weight Loss 
 R Hx Treatment of Latent TB Infection: Year: _____ Months Rx: _____  R Night Sweats  R Persistent Fatigue/Malaise 
City/state where previous treatment received:  R Chest Pain  R Other S&S: _____________________________ 
 R Smoking  R Other:  R NO SYMPTOMS OF ACTIVE DISEASE NOTED 
Current non-TB Medications: 
RISK HISTORY: 
HIV Status:  R Unknown  R Known  RTest Done, Results not shared 
Check “Yes”, “No” or “Unknown” for each of the following: 
Yes No Unknown 
 R  R  R Close contact to a person with active TB  RWithin the past 2 years  RMore than 2 years ago 
Source Case Name, LAST: , FIRST: 
 R  R  R Recent Converter (within past 2 years: > 10mm change 
 R  R  R Abnormal chest X-ray, consistent with old TB 
 R  R  R Newly arrived immigrant from any country with Class A/B TB (Check Class):  RClass A  RClass B1  RClass B2 
 R  R  R Non-US born person from country with a high prevalence of TB: 
(Africa, Asia except Japan, Central/South America, Eastern Europe, Caribbean, Middle East) 
 R  R  R Living, working, or extensive travel outside the USA within past 5 years to country with a high prevalence of TB 
 R  R  R Patient has one or more of the following underlying medical conditions: (Check all that apply) 
 RInsulin-dependent Diabetes Mellitus  R Steroid Therapy  R Malignancy (Cancer of head, neck, lung) 
 RChronic Renal Disease/Hemodialysis  R Silicosis  R Hematologic Disorders (Leukemia, Lymphoma) 
 RGastrectomy / Jejunoileal Bypass  R Organ Transplant  R Weight Loss >10% of ideal body weight 
 R  R  R Resident of a high-risk setting within the past year: (Check all that apply) 
 RPrison/Jail  RLong Term Care  RHomeless Shelter 
 R  R  R Medically under-served: (Check)  RHomeless  RMigrant worker  ROther: _________________ 
 R  R  R Substance Abuse within the past year: (Check all that apply)  RIV Drug Use  RExcessive Alcohol Use 
 RCrack/Cocaine/Other 
 R Anergic (with a risk factor for TB) 
COMMENTS: 
Signature: ,  R M.D. Signature:  R .N. 
8/00 FORM MDPH - TB04A 
MEDICAL RECORD 
Instructions for completing the TB HISTORY FORM 
General Instructions: The purpose of this form is to collect baseline information on the patient’s demographics, medical history, and 
risk factors for TB. This form is only completed for the initial visit. The clinic or health department personnel may fill it out at the 
time of the clinic visit or prior to the visit. A referring health care provider could also complete it. Please print legibly. 
These instructions address areas that may not be self-explanatory or have special instructions. Please fill form out as completely as 
possible. Optional fields are included primarily for clinic use as requested during piloting at clinic sites; most of the optional fields 
will not be entered into the Division’s database. Areas that are required are specifically noted in these instructions. 
TB Record #: Leave blank. The Division completes this upon data entry. 
Identification demographics (left top box): Printing is faint, so addressographs can be used. 
All bolded fields in this section are required. 
Date and TB Clinic name: Required. 
Referral Source Section: Source and Primary Care Provider fields are optional – for clinic use. 

Civil Surgeon Referral – Immigrants who are adjusting their immigration status in the US are required to complete a medical

screening. Civil Surgeons (physicians designated by Immigration and Naturalization Service) must plant and read a PPD on each

applicant over the age or two. Any applicant with a reaction of 5MM or greater needs to be further evaluated at the TB clinic. Check

this box. 

Demographic Data: Required. 
Employment Data: Check as many as apply with the exception of ‘Unemployed’ (no other box may be checked except student, if 
applicable). If a person is unemployed due to retirement, please check the ‘Retired’ box. ‘Employed at’ (place of employment) is an 
optional field – for clinic use. 
Medical History: 
History of Hepatitis: Check if pre-existing hepatitis (not due to TB drugs) and type A, B, or C. 

‘City/state where previous treatment received’, ‘Smoking’, ‘Other’, and Current non-TB Medications’ are optional fields – for clinic 

use. 

Symptoms: Required. 
Risk History: Required. 

HIV Status: Check appropriate box for patient’s knowledge of his/her HIV status. Patients who do not know their HIV status need to

have a risk assessment done, with referral to Counseling and Testing services if an HIV risk is identified (document on Initial Clinic 

Evaluation Form). 

Check ‘Yes’, ‘No’, or ‘Unknown’ for each risk factor. For risk factors with sub- boxes, check all that apply (at least one sub-box

must be checked). 

Steroid Therapy: Higher risk for progression to disease associated with prolonged high-dose steroid therapy:

> 15 mg/day of prednisone (or its equivalent) > 1 month or > 40 mg/day for > 2 weeks. 
Comments: Optional for clinic use. 
Signature: Signature(s) is (are) required for legal purposes. 
Distribution:  The Initial Clinical Evaluation Form and the TB History form should be distributed together, not separately. Original 
copy to Medical Records, a copy to the local health department of the patient’s residence, and a copy to the TB Division, 
Massachusetts Dept. of Public Health, State Laboratory Institute, 305 South St., Jamaica Plain, MA 02130. 
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH 
DIVISION OF TUBERCULOSIS PREVENTION AND CONTROL 
TB RECORD # CASE/SUSPECT FOLLOW UP FORM 
Hospital I.D. 
NAME, LAST: FIRST: 
CITY: D.O.B.  /  /  Sex: M F 
Complete for Change of Address or Phone only 
Street State 
City Zip Code 
Phone ( ) 
 T Date of Visit: / / 
 T B Clinic: 
Type of Visit: A - MD Visit B - Nurse Visit 
A1 x-ray Clinic/BOH 
A2 w/o x-ray Home Visit 
 T Private Provider: 
IF NO LONGER ON CHEMOTHERAPY  - COMPLETE THIS BOX ONLY 
 T Completed mos therapy: / / 
 T Incomplete chemotherapy reason: 
 T Moved, records referred (complete address change) 
 T Lost, unable to locate 
 T Died: TB  Not TB 
 T Other: 
 T Discharged from clinic  T Letter of discharge given to patient 
DRUG MONITORING: 
Assessment of Adverse Reactions: Check if present 
 T Unexplained Anorexia  T Rash 
 T Nausea/Vomiting  T Fever > 3 days 
 T Abdominal Tenderness  T Peripheral Neuropathy 
 T Persistent Fatigue  T Vision Changes 
 T Malaise  T Hearing Changes 
 T Dark Urine  T Headache 
 T Jaundice/Icterus  T Hair Loss 
 T Other S&S: 
 T NO ADVERSE REACTIONS NOTED 
Baseline ALT: 
ALT Result:  T WNL  T ABNL  T Not Done /Ordered 
Comments: 
ADHERENCE ASSESSMENT: 
 T reatment Adherence Assessed  T Urine Checked for INH/RIF 
Interrupted Therapy:  T Yes: # of Doses  T No 
PLAN: 
Continue:  T Self-Administered Therapy  T Directly Observed Therapy 
Start Directly Observed Therapy:  T Daily  T Intermittent: X/Week 
Person(s) performing DOT: 
 T Hold Meds temporarily due to:  T Abnormal ALT  T Side Effects 
 T Patient Education Reinforced: 
Sputum ordered:  T Yes  T No Chest X-ray ordered:  T Yes  T No 
Other Tests Ordered: 
CLINICAL STATUS:  T Improving  T Worsening  T No Change 
Weight: 
Comments: 
Follow-up Chest X-Ray:  Date:  / /  T Not Done 
Results:  T Normal  T Abn/Cavity  T Abn/Non-Cavity 
Status:  T Stable  T Improving  T Worsening 
Brief description of findings: 
Bacteriology:  T No Bacteriology Pending 
Source: Date Collected: / / 
Smear Result:  T Neg  T Pos  T Pending 
Culture Result:  T Neg  T Pos  T Pending 
Sputum Conversion Documented:  T No  T Yes te: / / 
No Positive Bacteriology - Evidence of Active TB: 
 T Clinical Response  T X-Ray Change 
 T Epidemiologic Link  T Pathology Only 
Details: 
Classification Status:  T Case - Class 3  T Suspect - Class 5 
Disease Site(s):  T Pulmonary  T ExtraPul: 
 T Active TB ruled out: _____ Not TB _____ Old TB _____Class 2 
Da
MEDICATION STATUS: mos. completed,  mos. remaining 
DRUG FREQ START STOP 
RESTART 
Rifater 
Rifamate 
INH 
RIF 
PZA 
EMB 
DOSAGE 
Next Visit: Country of Birth: 
 T Interpreter needed next visit: Language: 
Comments: 
Signature: _____________________________________________________ T R.N.  T M.D. Toll-Free Reporting Number: 1-888-MASSMTB (627-7682) 
10/99 FORM MDPH - TB05 MEDICAL RECORDS 
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH 
DIVISION OF TUBERCULOSIS PREVENTION AND CONTROL 
TB RECORD # _____________________ PREVENTIVE THERAPY FOLLOW UP FORM 
Hospital I.D. 
NAME, LAST: FIRST: 
CITY: __________________________D.O.B. /  / Sex: M F ____ 
COUNTRY OF BIRTH: ______________________________________  R Contact 
Complete for Change of Address or Phone only 
Street State 
City Zip Code  ____________ 
Phone ( ) 
Date of Visit: / / 
TB Clinic: 
Type of Visit: A - MD Visit B - Nurse Visit 
___ A1 x-ray Clinic/BOH 
___ A2 w/o x-ray  Home Visit 
No Visit: ____ ecord review only 
Preventive Therapy Status 
 R No longer on therapy Complete Part A only 
 R Still on therapy  RComplete Part B 
R
 R Last clinic visit - to complete therapy on: / / 
 R Letter of Discharge given to patient 
PART B: MEDICATION STATUS: 
mos. completed, mos. Remaining 
DRUG FREQ START STOP RESTART FINAL STOP 
DATE DATE DATE DATE 
INH 
RIF 
DOSAGE PART A: COMPLETE IF NO LONGER ON THERAPY 
 R Completed mos:  / / 
 R Incomplete preventive therapy reason: 
 R Diagnosed with active TB disease 
 R Moved, records referred (complete address change) 
 R Lost, unable to locate 
 R Died 
 R Discontinued by physician for adverse reactions 
 R Patient stopped on own initiative 
 R Discontinued on medical advice for other than adverse 
reactions 
Child’s Weight: 
Comments: 
 R Pregnancy  R Other: 
PART C: EVALUATION 
ADHERENCE ASSESSMENT: 
 R Treatment Adherence Assessed  R Urine Checked for INH/RIF 
PLAN: 
Continue:  R Self Administered Therapy  R Directly Observed Therapy 
Start Directly Observed Therapy:  R Daily  R Intermittent: _ X/Week 
 R Hold Meds temporarily due to:  R Abnormal ALT  R Side Effects 
 R /O Pregnancy 
 R Patient Education Reinforced about: 
 R Tests Ordered: 
DRUG MONITORING: 
Assessment of Adverse Reactions: Check if present 
 R Unexplained Anorexia  R ash 
 R Nausea/Vomiting  R Fever > 3 days 
 R Abdominal Tenderness  R Peripheral Neuropathy 
 R Persistent Fatigue  R Jaundice/Icterus 
 R Malaise  R Dark Urine 
 R Headache  R Hair Loss 
 R Other S&S: 
 R NO ADVERSE REACTIONS NOTED 
Baseline ALT: 
ALT Ordered:  R Yes  R No 
ALT Result:  R WNL  R ABNL  R Not Done 
Other Test Results: 
Comments: 
Comments: 
Next Visit: ______/______/______ 
 R Interpreter needed next visit: Language: 
Signature:  R .N.  R M.D. 
10/99 FORM MDPH - TB06 
MEDICAL RECORD 
Massachusetts Department of Public Health Reporting: (617) 983-6989 
Division of Tuberculosis Prevention and Control 1-888-MASS-MTB (Toll Free) 
305 South Street Jamaica Plain, MA 02130 FAX: (617) 983-6990 
All Reporting Confidential 
TB Case / Suspect Reporting Form 
Please Circle, where appropriate: 
Patient Name: ________________________, ____________________ Sex: M F Birth Date:_________________ 
(last) (first) 
Street Address: _______________________________ City/Town : _________________ State:______ Zip:_________ 
Tel: (Home) (____)______________ Place Of Birth: ___________________ Primary Language:_________________ 
Work Place:__________________ Tel:(____)___________ Next of Kin:__________________ Tel:(____)____________ 
Mantoux (PPD) Test: Done Not Done  Unknown Date Performed:_______________ Results:______ MM 
Chest X-Ray: Done Not Done Unknown Date Performed: ________________ 
Results of Chest X-Ray: Normal Abnormal, Non-Cavitary Abnormal, Cavitary 
Site(s) of Disease: ____________________________ Type of Specimen Collected: _________________________ 
Date Collected: ______________ 	Smear Results: Positive Negative Unknown Not Done 
Culture Results: Positive Negative Unknown Not Done 
Medications Begun: Yes No Unknown Date Medications Started: ___________________ 
Isoniazid (INH): ___________Mg Rifater (RFT)  (fixed combination of INH, RIF, PZA): ________Tabs 
Rifampin (RIF): ___________Mg Other: ___________________________________________________ 
Pyrazinamide (PZA): _______Mg Other: ___________________________________________________ 
Ethambutol (EMB): ________Mg Other: ___________________________________________________ 
Is Patient Hospitalized?  Yes No Hospital: ____________________ City/Town: __________________ 
Adm. Date: ______________ Estimated Disch. Date: ______________ Hospital Record #: _______________ 
Discharge Planning Contact Person: _____________________________________ Tel: (_____)_____________ 
Person Completing Form: ____________________________ Tel: (_____)___________ Date: __________________

Agency/Facility Name: ______________________________________________________

Primary Health Care Provider: __________________________________________ Tel: (_____)_______________ 

TB Care Provider: _____________________________________________________ Tel: (_____)_______________

Comments: _______________________________________________________________________________________

_________________________________________________________________________________________________

_________________________________________________________________________________________________

8/97 Form MDPH TB07 OVER:  TB Reporting Instructions, Information and Services 
TB Reporting Instructions, Information and Services 

(617) 983-6970 - main number - Division of Tuberculosis Prevention and Control 

Reporting - 24 hour lines: (617) 983-6989, 1-888-MASS MTB (toll free), FAX: (617) 983-6990 
(Regulation 105 CMR 365.500 or 105 CMR 300.140 -D) 
1. Notify the Division within 24 hours of all confirmed and clinically suspected cases of TB 
2. Fax / phone notification necessary for: Hospital patients and others requiring discharge planning 
Standard Tuberculosis Treatment for Active Disease 
For all TB Cases and Suspects: begin with four drugs until drug sensitivities available 
(Isoniazid, Rifampin, Pyrazinamide, Ethambutol or Streptomycin) 
Fixed Combination Drugs: recommended when patient on daily doses 
Rifater (INH, RIF, PZA) initially; Rifamate (INH, RIF) for continuation phase 
Failing Regimen: To prevent resistance, always add at least two TB drugs at the same time 
Consultation and list of Free TB Clinics available at the Division of TB Prevention and Control 
Case Management Services 
Nurse Case Manager required for all cases and suspects: Assigned by the local health department 
Coordinates medical, nursing, outreach, and social service systems needed to begin and 
complete appropriate therapy 
Responsible for case and contact investigations, nursing care plans, and patient education 
Arranges for Directly Observed Therapy (DOT) when indicated 
State regional nurses collaborate with local nurses regarding case management services 
Discharge Planning 
(Regulation 105 CMR 365.600 requires TB discharge planning in collaboration with state and local health departments) 
Starts When: TB diagnosed or suspected (clinical/laboratory evidence or patient on TB drugs) 
Pre-Discharge Conference Required: Include local health department nursing case 
manager, providers and discharge planners 
Home assessment by local health department nursing case manager necessary to: 
1. Prevent putting potentially vulnerable household members at risk - especially children 
2. Coordinate community follow-up for continuation and completion of therapy 
Infectious Patients - Special Considerations: Call the Division of TB Prevention and Control 
OVER: TB Case/Suspect Reporting Card 
Name: Last: _________________, First: _______________ DRUG O’GRAM

Year: _________ 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
DRUG Month 
Smear (- / +) 
Culture (- / +) 
Sensitivities (√ = done) 
RIFATER X--X = drug ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
RIFAMATE S = sensitive ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
ISONIAZID R = resistant ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
RIFAMPIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
PYRAZINAMIDE ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
ETHAMBUTOL ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
STREPTOMYCIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
KANAMYCIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
CYCLOSERINE ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
ETHIONAMIDE ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
PAS ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
OFLOXACIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
CIPROFLOXACIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
CAPREOMYCIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
RIFABUTIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
AMIKACIN ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
OTHER ________ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
OTHER ________ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ 
MDPH-TB09 


  
DIVISION OF TB PREVENTION & CONTROL                                                        MONTH 
OF_____________________ 
                                                                         DIRECTLY OBSERVED THERAPY (DOT) LOG 
 
 
Patients Name:____________________________________         Start Date:____/____/____  Designated Days/Times:___________________________ 
 
MEDS-DOSE-FREQ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
ISONIAZID                                
                                
RIFAMPIN                                
                                
ETHAMBUTOL                                
                                
PYRAZINAMIDE                                
                                
PYRIDOXINE                                
                                
LEVOFLOXACIN                                
                                
OFLOXACIN                                
                                
STREPTOMYCIN                                
                                
KANAMYCIN                                
                                
PAS                                
                                
ETHIONAMIDE                                
                                
OTHER                                
                                
                                
                                
 
 COMMENTS: 
 
 
 
 
 
 
                              
Codes:                     (0) Out of medication           (R) Refused          (S) Sick/Unable to take medicine        (N) Not Home    ) Weather 
 
HCW Signature:________________________________   s:_______       Patient  ______________________________  itials:______ 
 
5/99 FORM MDPH – TB11 
 
(W
Initial Signature:_ In

Patient Contract for Self-Administered Therapy 
Tuberculosis (TB) is a curable and preventable disease. I know that I have TB and need to be 
treated. I agree to the following conditions: 
1. I will take my pills as prescribed by my doctor, for as long as needed. 
2. I will keep all my appointments with the clinic, doctor, nurse and/or outreach worker. 
3. I will have all required medical tests, such as x-rays, sputum, urine and blood tests. 
I understand that if I fail to keep my appointments and take my pills that I may spread the disease 
to others, including my family and friend. If this happens, I will need directly observed therapy 
(DOT) where someone watches me take my pills or I may need to be hospitalized. 
Case Manager Signature: 
Patient Signature: 
05/99 FORM MDPH – TB12 

Patient Contract for Directly Observed Therapy 
Tuberculosis (TB) is a curable and preventable disease. I know that I have TB and need to be 
treated. I understand that the health department nurse will watch me take my pills (directly 
observed therapy - DOT) and I agree to the following conditions: 
4.	 I will keep all my DOT appointments with the nurse and/or outreach worker and take my 
pills as prescribed by my doctor, for as long as needed. 
5. I will keep my appointments with the clinic and doctor. 
6. I will have all required medical procedures, such as x-rays, sputum and blood tests. 
I understand that if I fail to keep my appointments and take my pills that I may spread the disease 
to others, including my family and friends, and that I may have to be hospitalized. 
Case Manager Signature: 
Patient Signature: 
05/99 FORM MDPH – TB13 

HIV RISK ASSESSMENT TOOL 

Patient Initials: _____ _____ Date of Birth: ______/______/______ 
Assessment Date: ______/______/______ 
Use of this High Risk Assessment Tool: 

4This form is designed to assess the TB patient’s HIV risk. 

4It is preferable for the questions to be asked by a nurse or physician. 

4Patients should fill out the form only if there are no language or literacy barriers. 

4The questions on the reverse side should be read aloud to the patient and the patient response 

should be marked in the appropriate box. 
4The form should then be placed in the patient chart. 
4Anyone who answers yes to questions 1-7 and 10 should be referred for HIV counseling and 
testing. 
FOR OFFICE USE ONLY: 

____ HIV risk assessment performed 

____ HIV risk assessment previously performed 

____ HIV risk assessment documented in chart 

____ HIV risk assessment form in chart 

____ HIV counseling and testing referral made: ____/____/____ 

____ performed on site 
____ performed at another site where_______________________________________ 
3/99 MDPH-TB14 
To be read aloud to patient before beginning HIV risk assessment: 
“So that you get the best care possible in the TB clinic, we need to ask some questions about 
your TB history and about activities that can put you at risk for HIV. Having TB infection does 
not mean you are at greater risk for HIV. But if you already have both TB infection and HIV, 
you are more likely to get active TB disease. So, part of our job is to make sure every patient 
seen in this TB clinic knows what the risks for HIV are and is asked about those risks. We know 
that asking these questions may make you feel uncomfortable but please remember that every 
patient is asked the same HIV questions, no matter what age, race, gender, or what country they 
are from. I will now read the questions. Please answer yes or no as it applies to you. Your 
answers are kept confidential.” 
HIV Risk Assessment Questionnaire 
1) Do you think you are at risk for HIV? Yes_____ No_____ 
2) Sometimes doctors and nurses in different parts of the world cannot get clean needles and 
equipment for their patients. This can put people at risk for HIV. Do you think this is a risk for 
you? Yes_____ No_____ 
3) People are at risk for HIV if they use/used to use unclean needles, share/used to shared 
unclean needles or their partner uses/used to use unclean needles. Do you think this is a risk for 
you? Yes_____ No_____ 
4)	 People or their partners who do not regularly use a condom during sex with someone at risk 
for HIV are themselves at increased risk for HIV. Do you think this is a risk for you? 
Yes_____ 
No_____ 
5)	 Having sex with people who inject drugs or having sex with men who have sex with men 
increases the risk for HIV. Do you think this is a risk for you? Yes_____ No_____ 
6) 	 Having sex with many people or having sex with someone who has had many sex partners 
increases the risk for HIV. Do you think this is a risk for you? Yes_____ No_____ 
7) 	 People who had a blood transfusion or received blood products since 1978 are at increased 
risk for HIV. Have you had a blood transfusion or received blood products since 1978? 
Yes_____ No_____ 
If yes, what year? ______________Where______________________________________ 
8) Would you like to know more about condom use education? Yes_____ No_____ 
9) Would you like more information on HIV? Yes_____ No_____ 
10) Would you like a referral for HIV counseling and testing? Yes_____ No_____ 
DRUGS TO TREAT TB: DOSES AND SPECIAL CONSIDERATIONS

FIRST LINE TB DRUGS 
Drug Twice Weekly Route Reactions 
Adult Dose Adult Dose 
Isoniazid (INH) 5 mg/kg 15 mg/kg P.O./ I.M. hepatotoxicity/hepatitis, peripheral, flu-like 
Max. 300 mg Max. 900 mg syndrome, neuropathy, hypersensitivity, 
Rifampin (RIF) 10 mg/kg 10 mg/kg P.O./I.V. Orange discoloration of urine and other 
Max. 600 mg Max. 600 mg secretions, nausea, vomiting, hepatitis, 
fever, purpura (rare), reduces levels of many 
drugs: Protease Inhibitors, birth control pills, 
Methadone, Warfarin, and Theophylline 
Metformin 
Rifamate (RFM) two capsules N/A P.O. Same as for Isoniazid and Rifampin 
(Isoniazid and Rifampin) 
A fixed-dose combination 
of 150 mg Isoniazid and 
300 mg Rifampin in each 
capsule 
Pyrazinamide (PZA) 15-30 mg/kg 50-70 mg/kg P.O. hepatotoxicity, hyperuricemia, arthralgias, 
Max. 2 Grams Max. 4 Grams skin rash, gastrointestinal irritation 
Rifater (RFT) under 99 lb. - four tablets P.O. Same as for Isoniazid, Rifampin, and 
(Isoniazid, Rifampin, and 99 - 120 lb. - five tablets Pyrazinamide 
Pyrazinamide) over 120 lb. - six tablets 
A fixed-dose combination 
of 50 mg Isoniazid, 
120 mg Rifampin, and 
300 mg Pyrazinamide 
in each tablet 
Ethambutol (EMB) 15-25 mg/kg 50 mg/kg P.O. optic neuritis, decreased visual acuity and 
red-green color discrimination, skin rash 
Streptomycin (SM) 15 mg/kg) 25-30 mg/kg I.M. ototoxicity, nephrotoxicity, hypokalemia 
Max. 1 Gram Max. 1.5 Grams 
(10 mg/kg up to 750 mg for persons 
age 60 and over) 
Daily Adverse 
MDPH-TB15 

SECOND LINE TB DRUGS 
Drug Daily Adult Dose Route Adverse Reactions 
Kanamycin, Amikacin, 15-30 mg/kg I.M./I.V. renal and auditory toxicity, vestibular 
Capreomycin toxicity (rare), hypokalemia 
Ethionamide 15-20 mg/kg P.O. gastrointestinal disturbance, arthralgias, 
500 –1000 mg daily hepatotoxicity, hyperthyroidism, metallic 
in divided doses taste and distorted smell, sever acne 
Cycloserine 15-20 mg/kg P.O. psychosis, personality changes, rash, 
250-1000 mg daily Impaired coordination, convulsions (rare), 
divided doses depression, increases Dilantin levels 
Para-amino salicylate (PAS)150 mg/kg P.O. gastrointestinal disturbance, sodium load, 
8-12 Grams daily in, Tablets, powder, increases Dilantin levels, hemolytic 
anemia divided doses or granules in patients with G6PD deficiency 
Ofloxacin 400-800 mg daily in P.O./I.V. bolus abdominal cramps, nausea, diarrhea 
divided doses 
Ciprofloxacin 750-1500 mg P.O./I.V. bolus abdominal cramps, nausea, diarrhea, rash, 
Headache, photosensitivity, insomnia 
Rifabutin- used as an 150 mg daily P.O. fever, headache, flu-like syndrome 
alternative to Rifampin for gastrointestinal symptoms, decreases AZT 
HIV positive persons on serum levels 
Protease Inhibitor therapy 
(use with Indinavir only) 
Source Case Investigation Policy and Procedure 

Latent Tuberculosis Infection (LTBI) in Children less than 1 year of age 

Massachusetts Policy: 
The Massachusetts Department of Public Health, Division of Tuberculosis Prevention & Control’s policy is to 
perform source case investigations for any child less than 1 year of age diagnosed with latent tuberculosis 
infection. 
Rationale: 
The Massachusetts Advisory Committee for the Elimination of Tuberculosis (MACET) views source case 
investigation as fundamental to preventing tuberculosis in children. When a child has latent TB infection, we 
know that TB was transmitted relatively recently. The person with infectious TB who is responsible for 
transmitting the M. tuberculosis organism to the child is called the source case. Source case investigation is a 
method used to find the source of TB transmission when recent transmission is likely. The younger the child, 
the greater the chance of locating the source case, since the infection is more likely to have been recent and an 
infant’s circle of contacts is usually much smaller than an older child’s.  Once the source case is found, he or 
she should be treated to prevent further spread of tuberculosis to others. 
Procedure: 
Conduct a source case investigation for children, less than 1 year of age who have a positive tuberculin skin test 
and who have not been identified as a close contact to a known suspect/case of infectious tuberculosis. 
1.	 Identify members of the child’s household and others who have had close continuous contact with the child 
(e.g. babysitters, day care staff, friends or family), or with whom the child spends a significant amount of 
time. 
2. Evaluate anyone with signs and symptoms of TB or with a history of TB. 
3.	  Refer child’s contacts for a medical evaluation if symptomatic or with a positive reaction to the tuberculin 
skin test. The evaluation is preferably done at a TB clinic. 
NOTE: All children with LTBI, regardless of age, should be evaluated for treatment. 
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